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Despite decades of work, Duchenne Muscular Dystrophy (DMD) remains a deadly 
disease with no cure. Recent advances in stem cell biology, immunology, and 
bioengineering suggest an interdisciplinary approach to the treatment of DMD. Towards 
this end, we created a multifunctional hydrogel composed of hyaluronic acid and 
skeletal muscle extracellular matrix that is cytocompatible, injectable, and 
biodegradable. The hydrogel facilitates the controlled release of myostatin inhibitors in 
vitro and increases their bioactivity in vivo. The hydrogel also promotes macrophage 
polarization towards CD206 expression, elevates anti-inflammatory cytokine levels, and 
co-injection of hydrogel with myostatin inhibitor yields a significant increase in Foxp3+ 
regulatory T cells. Finally, human embryonic stem cell derived myoblasts transplanted 
with the hydrogel demonstrated greater survival at 7-10 days post-injection, and 
increased engraftment after 4 months in immunodeficient dystrophic mice. Overall, this 
study represents a promising advance in regenerative medicine therapies for DMD. 
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In Chapter 1, I will introduce Duchenne Muscular Dystrophy (DMD), current and future 
treatment options for DMD including cell therapy and myostatin inhibition, the role of 
the immune system in skeletal muscle repair and regeneration, and the application of 
biomaterials and regenerative medicine principles to skeletal muscle. Chapter 2 
describes the synthesis of the materials utilized in this study, the fabrication of an 
injectable biomaterial-based hydrogel, and its initial characterization in vitro and in vivo. 
Cytocompatibility, biocompatibility, and growth factor delivery are assessed. Chapter 3 
characterizes the effects of the hydrogel and myostatin inhibitor on the local immune 
microenvironment in dystrophic mice, in terms of immunofluorescence visualization, 
cytometric characterization of local cell populations, and cytokine expression. Chapter 4 
describes work characterizing human pluripotent stem cell derived skeletal muscle 
myoblasts and the application of the hydrogel to skeletal muscle cell therapy. Finally, 
Chapter 5 presents the conclusion of this work and describes potential future 









Duchenne Muscular Dystrophy (DMD) 
Skeletal muscle disorders pose a significant public health burden, decreasing the quality 
of life of hundreds of thousands of patients worldwide [1]. The most common of these 
disorders is Duchenne Muscular Dystrophy (DMD), an X-linked recessive disease which 
affects approximately 1:5000 boys annually [2]. Due to mutations in the dystrophin 
gene, DMD patients have a complete absence of the dystrophin protein, which has key 
structural and signaling roles [3]. Without dystrophin, skeletal muscle undergoes a 
constant cycle of degeneration and regeneration, ultimately leading to replacement 
with fat and fibrotic tissue [4]. Depending upon genetic and environmental factors and 
standard of care, DMD patients generally lose the ability to ambulate as children, 
progressing to loss of upper limb function, and death by early adulthood due to 
cardiomyopathy and/or respiratory failure [4].  
 
Dystrophin is one of the largest genes in the human body, consisting of 79 exons and 8 
promoters [5] encoding a 427 kDa protein [6] that links the skeletal muscle sarcolemma 
to the underlying extracellular matrix through an N-terminal actin-binding domain, a 
cysteine-rich sarcoglycan-binding domain, and a C-terminal dystroglycan binding 
domain, all linked with a rod domain [7]. A variety of mutations can occur within the 
dystrophin gene, including missense [8] and nonsense [9] mutations; roughly 60% of 
mutations in DMD occur between exons 45-55 [10] and all have the potential to 
severely compromise the concentration and overall function of dystrophin. The 
dystrophin linkage is key to maintaining the complex architecture of skeletal muscle and 
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its ability to transduce force; absence or malfunction of dystrophin leads to a loss of 
stability between skeletal muscle and basal lamina, resulting in breakdown of 
components of the dystrophin glycoprotein complex, mis-localization of key proteins 
such as neuronal nitric oxide synthase, and compromise of the integrity of the 
sarcolemmal membrane [7], ultimately leading to ineffective skeletal muscle repair [4].  
 
Treatments and Therapies for DMD 
Duchenne patients are typically maintained on corticosteroids such as prednisone [11] 
and the recently-approved deflazacort [12] whose mechanism of action in this disease is 
not entirely understood but likely results in modulation of local inflammation.  However, 
as of 2017 two therapies to promote restoration of Dystrophin have received regulatory 
approval. Restoring even low levels of Dystrophin has the potential to confer clinical 
benefit, recapitulating the symptomatic profile of Becker Muscular Dystrophy, a less 
severe disease characterized by reduction of functional dystrophin but maintenance of 
some dystrophin function [13]. Ataluren, a compound designed to promote read-
through of premature stop codons [14] caused by nonsense mutations in the dystrophin 
gene, was approved by the EMA [15] despite a lack of consensus over the efficacy of the 
drug as determined by uncertainty over the use of luminescence-based assays to 
measure its effectiveness [16].  Eteplirsen, an agent designed to promote exon 51 
skipping and restore the reading frame of dystrophin [17], was also approved by the 
FDA [18] for use in DMD patients [19]. Despite the approval of these therapies, they 
appear to provide only a small benefit and are far from a cure [20].   
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Several other therapies for DMD are currently in various stages of development [20]. 
Dissociative immunomodulators such as VPB15 stabilize the sarcolemmal membrane 
and mediate inhibition of NF-κB without nonspecific immunosuppression, ameliorating 
DMD symptoms [21]. Several evaluated compounds upregulate the expression of 
compensatory proteins such as utrophin and biglycan that confer membrane-stabilizing 
functions. One modulator of utrophin, an autosomal analog of Dystrophin which 
maintains similar functions and can mediate disease severity in animal models of DMD 
[22], has recently completed phase I clinical trials [23]. Recombinant human biglycan, an 
ECM protein which has been shown to recruit the dystrophin glycoprotein complex 
proteins dystrobrevin, syntrophin, and neuronal nitric oxide synthase [24] as well as 
utrophin [25] to the sarcolemmal membrane, is also approaching clinical evaluation. 
 
Gene therapy approaches to replacing or editing non-functional Dystrophin have 
benefited from recent significant advances in molecular biology, particularly with the 
use of adeno-associated viral vectors (AAVs) [26]. Despite the 4.7 kb packaging limit of 
AAVs, micro- and mini- Dystrophin constructs [27] with truncated rod domains but 
functional N- and C- termini can be delivered via AAVs to treat dystrophic mice [28].  
Micro-dystrophin therapies are currently undergoing industrial development for 
eventual clinical application [29]. Alternative strategies utilize AAV-mediated delivery of 
the CRISPR-Cas9 genome editing system, a highly specific prokaryote-derived 
mechanism that can readily edit genomic DNA [30, 31]. Several groups have utilized this 
system to treat dystrophic mouse muscle [32, 33] and local muscle progenitor cells [34], 
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and utilized targeting vectors for muscle-specific delivery [35]. In addition to virally 
mediated gene editing and replacement, one additional strategy to replace Dystrophin 
has undergone significant development– cellular therapies. 
 
Cellular Therapies in DMD 
Young, healthy skeletal muscle has an enormous capacity for regeneration from resident 
and circulating myogenic precursor cells [36]. The primary progenitor population 
consists of Pax7+/MyoD- satellite cells (SCs), which are located between the basal 
lamina and the sarcolemma of individual muscle fibers.  These cells remain quiescent 
until stimulated to divide by cytokines or growth factors released during muscle injury 
[37].  Satellite cells divide asymmetrically, with one daughter cell repopulating the SC 
niche and the other undergoing either myogenic differentiation (expressing MyoD, 
Myf5, myogenin, and MRF4), or transdifferentiating into adipocyte or fibroblast lineages 
in ineffective regeneration [38, 39].  
 
Cell based therapies, which involve transplanting healthy skeletal muscle progenitor 
cells into diseased muscle, are widely considered as a potential treatment for DMD. 
Preclinical trials have demonstrated that transplanted muscle progenitor cells integrate 
with existing muscle, restoring the dystrophin protein in dystrophic mice [40] and dogs 
[41]. Notably, an alternative strategy involving the transplantation of bone marrow 
derived stem cells has also been used to restore dystrophin in dystrophic mice [42]. 
Dystrophin-deficient muscle progenitor cells derived from induced pluripotent stem 
7 
cells corrected ex vivo via micro-utrophin delivery [43] or CRISPR-Cas9 editing [44] have 
also been used to restore Dystrophin in vivo. Consequently, several cell types have been 
tested in various clinical trials, ranging from donor myoblasts from a father into affected 
progeny [45] to vessel-associated mesoangioblasts [46]. However, these trials have all 
failed to produce clinically significant outcomes [47]. The majority of transplanted 
muscle progenitor cells do not survive transplantation, and those that do are introduced 
into a fibrotic environment that inhibits their proper differentiation, integration, and 
maturation into myofibers [47]. 
 
Role of Myostatin Inhibition in DMD 
One class of compounds that has undergone significant development includes inhibitors 
of myostatin, an endogenous TGF-β family member that negatively regulates muscle 
regeneration [48, 49]. Genetic depletion or postnatal pharmacological inhibition of 
myostatin can lead to increased muscle growth [50, 51]. This phenomenon, which was 
first observed in mice, was confirmed in multiple species including humans, specifically 
in a hypermuscular child with a homozygous myostatin mutation whose Olympic 
sprinter mother also presented with a heterozygous myostatin mutation. Muscle growth 
has been observed with various pharmacological inhibitors of myostatin in healthy 
human subjects [51]. Blockade of myostatin results in faster regeneration of skeletal 
muscle and reduced fibrosis in mouse models of acute and chronic muscle injury [52]. 
Additionally, the Wagner lab has worked extensively with ActRIIB-Fc, a soluble form of 
activin receptor IIB conjugated to an Fc immunoglobulin domain, which binds free 
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myostatin and other activin proteins.  ActRIIB-Fc not only enhances myoblast 
proliferation and differentiation, but also inhibits fibroblast proliferation and collagen 
production [53].  Fibrosis of muscle is counterproductive to muscle regeneration and 
can be partially reversed by treatment with ActRIIB-Fc [54].   
 
Despite these promising pre-clinical results with ActRIIB-Fc, clinical trials evaluating the 
systemic delivery of similar soluble activin receptors were terminated due to 
unacceptable side effects which were determined to be off-target effects of the drug 
[55]. However, several other myostatin inhibitors have reached clinical stages and two 
are currently undergoing Phase 2 clinical evaluation for the treatment of DMD [20]. One 
of these compounds is a humanized [56] version of RK35, a highly potent and specific 
monoclonal neutralizing antibody against myostatin [57]. Although the effects of 
myostatin and its inhibition on skeletal muscle hypertrophy and fibrosis have been 
extensively characterized, relatively little is known about how these factors affect the 
immune microenvironment in skeletal muscle. 
 
Skeletal Muscle and the Immune System 
The complex cellular and signaling machinery of the immune system has, in addition to 
maintaining host defense against pathogens, been shown to play a significant role in the 
repair and regeneration of skeletal muscle [58]. Macrophages, which can adopt a variety 
of phenotypes, can exert numerous effects on skeletal muscle [59]. M1 macrophages, 
which infiltrate immediately following neutrophils in the earliest stages of muscle repair, 
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secrete IGF-1 which promotes the proliferation of local muscle progenitor cells [60]. Pro-
inflammatory cytokines upregulated during this phase not only perpetuate local 
inflammation, but also directly influence myogenesis. IFN-Υ signaling upregulates the 
class II transactivator CIITA, which directly binds and inhibits myogenin [61] and other 
myogenic factors [62]. TNF signaling upregulates the histone methyltransferase EZH2, 
leading to epigenetic silencing of Pax7 [63] and Notch1 [64]. 
 
Switching from the generally proinflammatory M1 phenotype to the generally 
proregenerative M2 phenotype is closely associated with downregulation of the cell 
surface marker CD86. This phenomenon is notably mediated by IL-10 released from 
Foxp3+ regulatory T cells [65]. The transition to the M2 phenotype eventually leads to 
the induction of IL-4 signaling and expression of the cell surface markers Fizz1 CD206 
[59]. M2 macrophages also facilitate phagocytosis and clearance of dead muscle fibers 
and other apoptotic cells such as neutrophils, Inhibiting the pro-inflammatory TNF and 
promoting TGF-B, which is key to secretion of ECM required for long-term repair [66, 
67]. Additionally at this stage, one group demonstrated that local eosinophils secrete IL-
33, potentially signaling local fibro-adipo progenitor cells (FAPs) to adopt a phenotype 
that promotes debris clearance and repair in cardiotoxin-injured mice, while also 
inhibiting their fatty, degenerative phenotype [68]. In conditions of chronic injury or 
disease these mechanisms can go awry, leading to pathological inflammation and 
fibrosis that can impede normal myogenesis [58]. This lends credence to the concept of 
targeting the immune system to resolve pathogenic inflammation in DMD [69]. 
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Biomaterials and Regenerative Medicine in Skeletal Muscle 
To promote skeletal muscle regeneration, recent advances in the fields of tissue 
engineering and regenerative medicine have greatly expanded the use of biomaterial 
scaffolds in a number of applications ranging from volumetric repair and delivery of cells 
and growth factors to skeletal muscle [70, 71] to 3D-printed artificial muscle constructs 
[72]. Encouraging results have been reported using small intestinal submucosal scaffolds 
with endothelial cells, murine myoblasts and foreskin fibroblasts [73], and an injectable 
polyethylene glycol-fibrinogen hydrogel with human mesoangioblasts [74, 75]. One 
group has utilized hydrogels to deliver VEGF and IGF-1 in a model of ischemia [6].  
 
Several studies have been reported using decellularized skeletal muscle extracellular 
matrix, created by removing cellular and nuclear material while retaining pro-
regenerative growth factors. This material has been utilized in numerous applications 
including skeletal [76] and cardiac muscle [77], and has been used to treat volumetric 
muscle loss [78]. Notably, the field of biomaterials-mediated regenerative immunology 
has characterized the role of these materials in modulating the immune system to 
induce pro-regenerative outcomes [79], including the use of extracellular matrix 
scaffolds to promote CD206 macrophage polarization [80] and type 2 immune signaling 
[81], facilitating myogenesis. These biomaterials could potentially be utilized towards 
the development of injectable hydrogels [82] that have the capability to deliver growth 
factors [70] and create a pro-regenerative immune microenvironment that can be 
characterized to determine the effects of the material on surrounding tissue [83]. 
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Overall Summary 
Here we utilize an injectable biomaterial composed of hyaluronic acid (HA), a 
glycosaminoglycan upregulated during muscle hypertrophy [84], and decellularized 
porcine skeletal muscle extracellular matrix, which has demonstrated considerable 
utility in previous regenerative medicine applications [78]. HA is conjugated to N-
hydroxysuccinimide [85], allowing it to readily form a cytocompatible hydrogel at 
physiological temperatures in vitro.  The hydrogel is injectable and biodegradable, and 
promotes the delivery of myostatin inhibitors [57] in vivo.  
 
Additionally, injection of hydrogel is associated with a shift in macrophage polarization 
away from CD86 and towards CD206 expression in both wild type and dystrophic mice, 
as well as the elevated expression of anti-inflammatory cytokines. When combined with 
a neutralizing antibody against myostatin, the hydrogel synergistically promotes the 
induction of regulatory T cells in the local immune microenvironment, revealing 
potentially novel insights into the interplay between the immune system, myostatin 
inhibition, and the host response to biomaterials. Finally, the hydrogel also promotes 
the viability and myogenic capacity of transplanted hESC derived skeletal muscle 
myoblasts [86], leading to some observed restoration of the dystrophin protein in 
dystrophic mice. By utilizing biomaterials to create a pro-regenerative environment, this 



























A number of biomaterials have been developed for tissue engineering and regenerative 
medicine in various applications, ranging from bone and cartilage to skeletal muscle.  
Here we describe the preparation of an injectable biomaterial, known as a hydrogel, 
utilized throughout this study.  The hydrogel consists of hyaluronic acid (HA) conjugated 
to N-hydroxysuccinimide (NHS), and decellularized skeletal muscle extracellular matrix 
(dSKM-ECM). These materials were combined to form a cytocompatible hydrogel in 
vitro, and determined to be injectable and biodegradable in vivo. Additionally, the 
hydrogel promoted the controlled release of myostatin inhibitors in vitro, and increased 
their bioactivity in vivo. Chapter 2 outlines the fabrication and characterization of an 














Hydrogels, defined as networks of “water-insoluble crosslinked hydrophilic polymers” 
[82], have been adopted by the field of tissue engineering for several applications in 
skeletal muscle, ranging from culturing muscle progenitor cells [87] to growth factor 
delivery [88] and cell delivery [74, 89, 90]. A number of materials can be used to create 
hydrogels, including hyaluronic acid, a glycosaminoglycan upregulated during skeletal 
muscle hypertrophy [84] that has been used as a hydrogel in cardiac tissue applications 
to deliver cardiomyocytes [85], as well as decellularized extracellular matrix, which has 
been used alone to form hydrogels that repair cardiac [91] and skeletal [92] muscle. 
 
Although myostatin inhibitors have demonstrated efficacy in ameliorating symptoms in 
an animal model of DMD [48], systemic administration of one soluble activin receptor 
during clinical trials led to telangiectasia and epistaxis, leading to termination of the trial 
[55]. In order to promote site-specific myostatin inhibition in conjunction with the 
longer-term goal of creating a microenvironment to promote muscle regeneration, we 
developed a hyaluronic acid / extracellular matrix hydrogel designed to be injectable, 
cytocompatible in vitro, and biocompatible in vivo. Functionality of the hydrogel as a 
drug delivery vehicle was tested utilizing RK35, a potent anti-myostatin antibody [57], as 
a candidate compound. 
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Materials and Methods 
HA-NHS Synthesis 
Hyaluronic acid functionalization with NHS (HA-NHS) was performed as described 
previously [85].  Briefly, 10% (w/v) sodium hyaluronate (MW 13-16 kDa, LifeCore 
Biomedical) was reacted with 67% N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
(EDC, Sigma) and N-hydroxysuccinimide (NHS, Sigma) in phosphate buffered saline 
(Gibco) at 37°C for 10 minutes.  The resulting mixture was then frozen at -80°C for 1 
hour, then precipitated using 100% ethanol pre-cooled to -20°C. Precipitate was 
centrifuged, washed with -20°C 100% ethanol 9 times, then dried under high vacuum 
overnight. Functionalization was confirmed by hydroxamate assay [93].  
 
Skeletal Muscle ECM Processing 
Skeletal muscle extracellular matrix (M-ECM) was prepared in the same manner as 
previously described [81]. Yorkshire porcine hindlimb skeletal muscle (Wagner Meats) 
was trimmed of fat and connective tissue, minced using a knife mill (Retsch) into pieces 
no larger than 5 mm, then rinsed with distilled water to remove blood and loose 
particulates. The tissue was then incubated with 3% peracetic acid (Sigma) for 1 hour 
under constant agitation, followed by replacement with fresh acid solution and an 
additional 3 hours of agitation at 37°C. Sample was re-equilibrated to neutral pH with 
several rinses of distilled water and verified with pH indicator strips (Macherey-Nagel), 
then transferred to 1% Triton X-100 (Sigma) + 2 mM sodium EDTA (Sigma) solution on a 
room temperature stir plate at 400 rpm for 3 days, changing the solution daily. The 
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sample was rinsed with distilled water until no bubbles formed from agitation, 
indicating complete removal of the Triton/EDTA solution, then transferred to 600 
units/mL DNAse I (Roche) + 10 mM magnesium chloride (J.T. Baker) + 10% Antifungal-
Antimycotic (Gibco) for 1 day. Tissues were rinsed with distilled water, frozen at -80°C 
overnight, then lyophilized for three days. A sample of the resulting dried particulate 
was fixed in formalin, embedded with paraffin, and sections were taken and stained 
with Hematoxylin and Eosin (Sigma) to verify proper decellularization. The remaining 
particulate was pulverized into a powder with a SPEX SamplePrep Freezer/Mill (SPEX 
CertiPrep) and stored at -20°C prior to use. Phenol chloroform extraction was used to 
isolate DNA and confirm endogenous DNA degradation using gel electrophoresis. 
 
Rheological Testing 
An ARES G2 Rheometer (TA Instruments) with a solvent trap plate, Peltier solvent trap, 
and evaporation blocker were used in the mechanical characterization of the material.  
All tests were performed at 37°C. Gelation testing was performed on 1 mL samples of 
freshly prepared HA-NHS (15 mg/mL), M-ECM (45 mg/mL), or 6% HA-NHS:M-ECM 1:3 
hydrogel. Gelation test parameters were determined as described previously [94] with 
frequency at 2.0 Hz and oscillation strain at 5.0%; storage and loss moduli were 
observed over the course of 250 minutes. Data were analyzed via ordinary one-way 




In vitro Cytocompatibility Assay 
In order to evaluate the cytocompatibility of the hydrogel, 0.5x106 LHCN-LUC7 
immortalized human myoblasts [95] were combined with 45 mg/mL M-ECM in sterile 
phosphate-buffered saline (PBS), then combined with 15 mg/mL HA-NHS in sterile PBS, 
yielding a final concentration of 0.5x106 cells / 1 mL 6% w/v HA-NHS:M-ECM 1:3 
hydrogel.  Cell-laden hydrogels were added to the wells of a 24-well plate, incubated at 
37°C for 50 minutes, then covered with 1 mL human myoblast medium (Medium 
199:DMEM 4:1 + S0% fetal bovine serum + 2% penicillin / streptomycin + 0.02 M HEPES 
+ 0.03 μg/mL ZnSO4 + 1.4 μg/mL Vitamin B12 + 0.055 μg/mL Dexamethasone + 2.5 
ng/mL HGF + 10 ng/mL bFGF). Cells were allowed to grow for four days, and then 
viability was determined using a Live/DEAD Assay Kit (Thermo Fisher). 2 sets of live and 
dead 10x channel images from n=4 100 μL gels were taken with an EVOS FL microscope 
(Thermo Fisher), live and dead cells present in each field were counted. Counts were 
used to calculate the percentage of live and dead cells, which were compared with a 
two-way ANOVA using Sidak’s multiple comparisons test in Prism (Graphpad). 
 
In vivo Degradation Assay 
6-week old female wild-type C57BL/6 mice (Jackson Laboratories) were anesthetized 
under constant isoflurane and their hind limbs were shaved.  Each limb was restrained 
and a 1 cm incision was made above the tibialis anterior muscle to expose the fascia. 50 
μL 6% HA-NHS:M-ECM 1:3 hydrogel was injected into the subfascial space of the tibialis 
anterior with a 1 mL tuberculin syringe (BD) fitted with a 22G needle (Exel). Both legs 
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were injected for each mouse, and wounds were closed with surgical staples (Roboz). 
n=2 mice were harvested at 7, 14, and 21 days post-injection, flash frozen with chilled 
isopentane, serially cryosectioned, stained with Hematoxylin and Eosin, and visualized 
with an Axio Imager.M2 microscope (Zeiss).  10x H&E images with 10% overlap were 
taken across the entire section and stitched with Image Composite Editor (Microsoft).  
 
Myostatin Inhibitor In Vitro Release Kinetics  
6% w/v HA-NHA:M-ECM 1:3 hydrogels loaded with 66.67 ng RK35 [56, 57] (Pfizer) were 
added to a 48-well plate (Corning), allowed to gellate at 37°C for 30 minutes, then 500 
μL collection medium (McCoy’s 5A + 0.1% bovine serum albumin) was added to each 
well. Collection medium was harvested at 1, 3, and 5 days post-encapsulation, combined 
with recombinant myostatin (R&D Systems) at 10 ng/mL, then incubated at 37°C for 30 
minutes. Each sample was analyzed via luminescence-based assay to measure myostatin 
bioactivity [96] on a Luminoskan Ascent luminometer (Fisher Scientific) and compared 
to a standard dilution curve of RK35 + myostatin to calculate the amount of RK35 
present, which was then used to calculate % RK35 released. N=3 gels were harvested 
per timepoint, and n=3 technical replicates were analyzed per sample.  
 
Myostatin Inhibitor In Vivo Bioactivity 
In order to verify the validity of saline vs. hydrogel controls, 4 month old dystrophic 
male mdx-5Cv mice (Jackson Laboratories) were injected with 50 μL PBS or 50 μL 6% w/v 
HA-NHS:M-ECM 1:3 hydrogel into the subfascial space of the left TA. Each contralateral 
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limb was used as an internal negative control. 5 days after injection all TAs were 
weighed and compared via student’s T test in Prism (Graphpad). In order to assess 
myostatin inhibitor activity, 2 month old dystrophic male mdx-5Cv mice (Jackson 
Laboratories) were injected with 50 μL PBS, 50 μL PBS + 10.75 μg RK35, or 50 μL 6% w/v 
HA-NHS:M-ECM 1:3 hydrogel + 10.75 μg RK35 (n=5 per group) into the subfascial space 
of the left TA muscle. Each contralateral limb was used as an internal negative control.  
 
5 days after injection all TAs were weighed and compared via one-way ANOVA with 
Tukey’s multiple comparisons test in Prism (Graphpad). RK35-injected TA muscles were 
flash frozen in chilled isopentane and cryosectioned. Two 7 μm sections from regions at 
least 300 μm apart were analyzed from each muscle.  Slides were fixed in cold 
methanol, blocked with 20% normal goat serum in 2% bovine serum albumin (BSA), 
then incubated overnight with primary antibody against embryonic myosin (DSHB 
F1.652-s, mouse IgG1 anti-MYH3). Primary antibody was removed, then slides were 
incubated with Goat Anti-Mouse Alexa Fluor 647 (Thermo Fisher) secondary antibody at 
1:500 in 20% NGS + 2% BSA for 1 hour at room temperature. Slides were rinsed in PBS, 
mounted in Vectashield + DAPI (Vector), and 20x immunofluorescence mosaics were 
taken with an Axio Imager.M2 microscope (Zeiss). Images were analyzed in ImageJ to 
determine overall cross-sectional area and embryonic myosin heavy chain signal in 
terms of integrated density. Slides stained without primary antibodies were used as a 
negative control, and the strongest eMHC signal field from one hydrogel+RK35 injected 
muscle was used as a positive control to set exposure constant at 13 ms. 
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Results  
Hydrogel synthesis and characterization. 
Hyaluronic acid was combined with N-hydroxysuccinimide (NHS) and reacted with 
carbodiimide, creating HA-NHS via formation of sulfo-NHS-esters from locally available 
carboxylic acid groups (Figure 2.1A). A hydroxamate assay was performed to verify 
conjugation, revealing that 22.41% of the carboxylic acid groups present on HA formed 
sulfo-NHS-esters (data not shown). Porcine skeletal muscle tissue was separated from 
fatty and connective tissue, rinsed, minced, and subjected to a standard processing 
protocol [81] to yield decellularized skeletal muscle extracellular matrix (M-ECM) (Figure 
2.1B). Decellularization was verified by extracting DNA from the processed ECM sample 
and comparing it to a standard DNA ladder, revealing that only small fragments of 
nuclear material remained (Figure 2.1C). Further characterization was performed by 
histological assessment of the processed ECM material, which revealed a lack of visibly 
apparent cellular and nuclear material after staining for hematoxylin and eosin (Figure 
2.1C). 30 mg/mL HA-NHS and 90 mg/mL M-ECM were combined to yield a final 6% w/v 
HA-NHS:M-ECM 1:3 (HA-ECM) composite which formed a hydrogel at physiological 
temperatures in vitro. Time sweep rheology [94] revealed a steady increase and 
eventual plateau of the hydrogel storage modulus not observed with either component 





Hydrogel cytocompatibility and biocompatibility. 
In order to assess cytocompatibility, immortalized human myoblasts [95] were 
combined with the hydrogel and seeded in vitro. Cell viability was assessed at 4 days 
post-encapsulation via Live/DEAD visualization of two fields in four gels (Figure 2.3A, 
Supplementary Figure 2.1), and almost no dead cells were observed (Figure 2.3B). The 
hydrogel was injected into the subfascial space above the tibialis anterior (TA) muscles 
of wild-type C57BL/6 mice in order to assess its biocompatibility in vivo. Labeling the 
hydrogel with blue dye allowed for visualization of the hydrogel spreading across the 
entire intertendinous space of the TA when injected subfascially (Figure 2.4A). Harvest 
and histological evaluation of hydrogel-injected muscles revealed that the hydrogel 
degrades over the course of 21 days in vivo with no long-standing myotoxic effects 
(Figure 2.4B). 
 
Hydrogel-mediated delivery of cells and myostatin inhibitors in vivo. 
Since biomaterials have demonstrated several applications in skeletal muscle, we 
assessed the multifunctionality of the hydrogel by determining its ability to deliver 
growth factors in vivo. Growth factor delivery was assessed with hydrogels containing 
the anti-myostatin antibody RK35 [57] both in vitro and in vivo (Figure 2.5).  A 
luminescence-based assay [96] was used to generate a standard curve of myostatin 
inhibition (Supplementary Figure 2.2), which was then used to quantify the amount of 
RK35 present in supernatant samples taken from RK35-laden hydrogels in vitro, allowing 
for determination of the percentage of RK35 release over time. Controlled release of 
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RK35 from the hydrogel was observed over the course of five days, peaking at 20% 
release of the encapsulated compound (Figure 2.5A). Mdx-5Cv mice, which serve as a 
model of Duchenne Muscular Dystrophy [97], were used to evaluate RK35 bioactivity 
when delivered to uninjured TA muscles via saline or hydrogel in vivo (Figure 2.5B-D, 
Supplementary Figures 2.3-2.4). Saline-injected muscles were demonstrated to have 
similar weights to hydrogel-injected muscles, and thus were deemed appropriate as a 
treatment-free control (Supplementary Figure 2.3). RK35-hydrogel injected muscles 
showed greater weight and overall cross-sectional area compared to muscles injected 
with RK35 in saline (Figure 2.5 B-C). Immunofluorescence labeling of embryonic myosin 
heavy chain (eMHC), a marker of regeneration, revealed greater eMHC signal density in 
muscles injected with RK35 and hydrogel compared to saline (Figure 2.5D, 













Given the previously demonstrated utility of biomaterial hydrogels in regenerative 
medicine applications [82] and drug delivery [98], we sought to apply these principles to 
the treatment of DMD.  Here, we have utilized the techniques of carbodiimide chemistry 
and tissue decellularization to create a hyaluronic acid / ECM composite hydrogel. The 
gel was demonstrated to be cytocompatible with immortalized human skeletal muscle 
myoblasts (Figure 2.3), injectable (Figure 2.4A), and biocompatible (Figure 2.4B).   
Additionally, the hydrogel facilitated the controlled release of the myostatin inhibitor 
RK35 in vitro (Figure 2.5A) and promoted its bioactivity in vivo (Figure 2.5B). 
 
Some limitations do arise in the preparation of each of the hydrogel component 
materials. Even though only 22.41% of the available carboxyl groups present on the 
hyaluronic acid backbone were reacted, this is in line with previous results describing 
this chemical conjugation to chondroitin sulfate [93] and actually exceeds the 16.67% 
conjugation previously observed with hyaluronic acid [85]. Despite extensive processing 
of porcine-derived skeletal muscle, some nuclear material remained (Figure 2.1C). 
Although it may not be possible to remove all exogenous nuclear material, the standard 
DNAse I treatment is sufficient to remove large fragments, leaving only small traces of 




Rheology (Figure 2.2) revealed that gelation of the material composite takes a relatively 
long time in vitro, and the low terminal storage modulus indicates that this is a relatively 
weak gel. Skeletal muscle itself adopts an elastic modulus of 13-18 kPa [70], roughly two 
orders of magnitude stronger than this material, which exhibited a peak storage 
modulus of approximately 30 Pa. However, the primary design factor of the hydrogel 
was not necessarily structural repair but implantation, creating a material that 
modulates the local environment to support the effective regeneration in vivo, 
complemented by localized delivery of the myostatin inhibitor. The fact that HA-NHS 
and decellularized skeletal muscle ECM were unable to individually exhibit gelation 
properties similar to that of the composite material demonstrates that some 
crosslinking does occur between conjugated N-hydroxysuccinimide groups on the HA 
backbone and locally available primary amines in the ECM.  
 
The increased viscosity of this material, as well as the opportunity for NHS groups to 
react with primary amines in local tissue, facilitates the retention of the hydrogel in situ, 
potentially contributing to the increased bioactivity of the myostatin inhibitor RK35 in 
vivo (Figure 2.5 B-D). Because the hydrogel itself does not swell appreciably (Figure 2.2), 
nor does it significantly contribute to the weight of injected muscles in vivo 
(Supplementary Figure 2.3), the observed increase in muscle weights and overall cross-
sectional areas was most likely due to the hypertrophic effects of myostatin inhibition 
associated with RK35 (Figure 2.5B-C). This was confirmed upon observation of the 
increased staining density of embryonic myosin heavy chain (Figure 2.5D). 
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RK35 is a highly specific, direct inhibitor of myostatin [56, 57], contrasted with ActRIIB-
Fc, a soluble activin receptor decoy which despite positive results in vitro has been 
previously tested and retracted from clinical trials due to side effects [55], presumably 
from off target effects on other activin signaling pathways. Although RK35 already has 
higher potency, specificity, and half-life compared to soluble activin receptors [56], 
targeted specific delivery to muscles most severely affected by DMD could still confer a 
number of benefits: further reduction of off-target effects, decreased overall 
concentrations of drug used to treat patients, and, in concert with the presence of pro-
myogenic growth factors in the locally crosslinked decellularized skeletal muscle 
extracellular matrix, the creation of a pro-myogenic microenvironment that could have 



























Figure 2.1. Hydrogel components. (A) Sodium hyaluronate (left) was reacted with N-
hydroxysuccinimide to form hyaluronic acid succinimidyl succinate (HA-NHS) (right). 
Chemical structures taken from Wikipedia.com and www.creativepegworks.com. (B) 
Yorkshire porcine skeletal muscle was processed to yield decellularized skeletal muscle 
extracellular matrix (dSKM-ECM). (C) dSKM-ECM characterization. (Left) DNA 
electrophoresis gel confirms removal of major nuclear material. (Right) H&E image of 
















Figure 2.2. Mechanical characterization of HA-ECM hydrogel. Time sweep rheology of 
HA-NHS, M-ECM, and hydrogel over 250 minutes. Frequency = 2.0 Hz, oscillation strain = 
5.0%. Peak storage (A) and loss moduli (B) shown in bar graphs, storage moduli shown in 
curve (C). Legend applies to all figures. N=3 samples per condition. Data represent 


































































Figure 2.3. Cytocompatibility of HA-ECM hydrogel. 0.5x106 LHCN-LUC7 immortalized 
human myoblasts were seeded into hydrogels in vitro and assessed for 
cytocompatibility after 4 days. (A) Fluorescence images of live (green) and dead (red) 
immortalized human myoblasts at 4 days post-hydrogel encapsulation in vitro. Scale 
bars = 200 microns. (B) Quantification of observed live and dead cells from 2x sets of 
































Figure 2.4. Injectability and biocompatibility assessment of HA-ECM hydrogel. (A) 
Subfascial injection of dye-labeled hydrogel (blue) into murine TA muscle spreads from 
tendon to tendon. (B) H&E mosaics of whole C57BL/6 WT TA muscles injected with 
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Figure 2.5. HA-ECM hydrogel delivery of myostatin inhibitors in vitro and in vivo. (A) 
Release kinetics of myostatin inhibitor (RK35) from hydrogels in vitro, quantified with a 
luminescence-based assay up to 5 days post-encapsulation. N=3 gels per timepoint. (B-
D) Increased bioactivity of hydrogel-encapsulated RK35 at 5 days post-injection in vivo. 
(B) Average injected TA weights. (C) Average injected TA cross-sectional areas. (D) 
Immunofluorescence images and integrated density quantification of embryonic myosin 
heavy chain (green) in injected TAs. Scale bars = 50 microns. Saline n=2, RK35 and 
hydrogel+RK35 n=5.  Legend applies to all figures. All error bars represent means +/- 
SEM. ** p < 0.01, *** p < 0.001, **** p < 0.0001. 








































































































































   
Gel 2: 
   
Gel 3: 
   
Gel 4: 
   
Supplementary Figure 2.1. Representative images used to determine cell viability in 
hydrogel. 0.5x106 LHCN-LUC7 immortalized human myoblasts were seeded into 
hydrogels in vitro and assessed for cytocompatibility after 4 days. Fluorescence images 
of live (green) and dead (red) immortalized human myoblasts at 4 days post-hydrogel 
encapsulation in vitro.  2 live and dead fields were imaged from N=4 gels. All images 





Supplementary Figure 2.2. TA204 + myostatin response curve.  Serum-starved TA204 
cells were treated with several concentrations of myostatin (160-0 ng/mL, top panel) or 
with 10 ng/mL myostatin and various concentrations of RK35 (0-10 nM, bottom panel).  
Response levels were determined by differential emission of luciferase. N=3 technical 






















































Supplementary Figure 2.3. Saline and hydrogel-injected TAs used to verify controls. 
N=5 TAs were injected with 50 μL PBS or hydrogel, harvested at 5 days post-injection, 































































Several studies have implicated the immune system as a significant mediator of skeletal 
muscle repair and regeneration, and extracellular matrix-based biomaterials have been 
shown to play a role in polarizing the immune microenvironment towards pro-myogenic 
outcomes. However, the study of the immune response to biomaterials has not been 
evaluated within the context of DMD. Towards this end, we have utilized a previously 
established method to characterize the overall immunological response to the HA-ECM 
hydrogel described in Chapter 2. The hydrogel promotes the infiltration of scaffold-
associated macrophages and expression of anti-inflammatory cytokines in both wild 
type and dystrophic mice. Notably, combining the hydrogel and myostatin inhibitor 
Rk35 affects T cell polarization, and yields a substantial increase in Foxp3+ regulatory T 
cells - an effect not observed with any individual component of the hydrogel or RK35 
alone Chapter 3 outlines the analysis of immune cell populations present around (and 
possibly influenced by the presence of) the hydrogel scaffold, known as the scaffold 
immune microenvironment, as well as the effects of the hydrogel on proximal systemic 









A number of recent studies [58] have explored the complex interplay between the 
processes of skeletal muscle repair and activation of the immune system, particularly 
within the context of DMD [69]. The population of immune cells and soluble factors 
such as cytokines form a distinct immune microenvironment that has direct effects on 
the process of myogenesis, ranging from effects on satellite cell proliferation and 
differentiation to normal versus pathological induction of fibrosis.  This has been further 
studied within the context of the response to biomaterials in skeletal muscle.  Previous 
work has demonstrated the presence of M2-like CD206+ scaffold-associated 
macrophages [83] modulated by biomaterials in skeletal muscle that work with type 2 
signaling through IL-4 and CD4+ T-cells to promote regeneration [81].  
 
Despite these advances, the immunological response to biomaterials has not been 
evaluated within the context of DMD, and the effects of myostatin inhibition on the 
dystrophic immune microenvironment are still unknown. Here, we evaluated the effects 
of the hydrogel described in Chapter 2, its individual components, and myostatin 
inhibitors on the immune microenvironment in wild type and dystrophic mdx mice. We 
used immunofluorescence and flow cytometry to characterize modulated cell 
populations, and qPCR to evaluate cytokine expression in local draining lymph nodes 
proximal to the injected biomaterial. Overall, we observed polarization towards a pro-
regenerative immune microenvironment in the presence of the hydrogel and myostatin 
inhibitor in mdx mice. 
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Materials and Methods 
Materials Implantation 
1 month old female WT C57BL/6 and dystrophic mdx-5Cv mice (Jackson Laboratories) 
were bilaterally injected with 50 μL PBS or 6% w/v HA-NHS:M-ECM 1:3 hydrogel. 2-5 
month old male dystrophic mdx-5Cv mice (Jackson Laboratories) were bilaterally injected 
with 50 μL PBS, 30 mg/mL HA-NHS, 90 mg/mL M-ECM, 6% w/v HA-NHS:M-ECM 1:3 
hydrogel, PBS + 10.75 μg RK35, or 6% w/v HA-NHS:M-ECM 1:3 hydrogel  + 10.75 μg 
RK35. In all cases, mice were anesthetized with isoflurane and shaved prior to injection. 
Each limb was restrained and a 1 cm cutaneous incision was made above the tibialis 
anterior muscle to expose the fascia. All materials were injected into the subfascial 
space of the tibialis anterior (TA) muscle with a 1 mL tuberculin syringe (BD) fitted with a 
22G needle (Exel). Both legs were injected for each mouse, and wounds were closed 
with surgical staples (Roboz). All animals were sacrificed at 1 week post-injection. 
 
Proximal Lymph Node Cytokine Analysis 
Upon harvest, inguinal lymph node pairs (n=4) were visually identified, isolated from 
each animal, and frozen. Lymph node pairs were then minced and homogenized in Trizol 
(Invitrogen). RNA was extracted from each sample with chloroform, and then isolated 
using an RNEasy Extraction Kit (Qiagen). RNA concentration for each sample was 
determined with a Nanodrop 2000 spectrophotometer (Thermo Scientific), and 1 μg 
RNA was used to produce cDNA using an iScript cDNA Synthesis Kit (Bio-Rad). qPCR was 
performed with PowerUP SYBR (Thermo Fisher) on a CFX Connect (Bio-Rad) with 
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primers diluted to 20 μm (Table 3.1). Data were analyzed as calibrated normalized 
relative quantities (CNRQ) over saline group for each genotype, and statistically 
compared via one-way ANOVA with Tukey’s multiple comparisons test in qBase+ 
(Biogazelle). Graphs were rendered in Prism (Graphpad). 
 
Immune Characterization  
Upon harvest, both tibialis anterior (TA) muscles were harvested from each animal. N=4 
animals from each group were used for FACS analysis, and n=1 spleen was processed 
and split for use in unstained, viability, single-color, and full-panel control samples. 
Samples were minced, then digested with Liberase TL (Roche) for 45 minutes or Liberase 
TM (Roche) with DNAse I (Roche) in RPMI-1640 medium (Gibco) for 30 minutes under 
constant agitation at 37°C. The resulting single-cell suspensions were filtered through a 
100 micron filter (Fisher Scientific) and counted with a Countess II FL (Thermo Fisher) 
(Supplementary Table 3.1). All samples were treated with ACK lysing buffer (Quality 
Biological), subjected to cytokine stimulation, stained with FACS antibodies (BioLegend, 
Thermo Fisher, or BD) and viability dye (eBiosciences) (Table 3.2-3.3), fixed in Cytofix 
(BD), and analyzed with an LSR II or Fortessa (BD). Data were analyzed and gated 
(Supplementary Figures 3.1, 3.4) in FloJo (Treestar) or Diva (BD), population 
percentages were calculated in terms of %CD45+ cells, then normalized to cell counts to 
yield absolute cell numbers. Overall mean fluorescence intensity (MFI) was also 
calculated for the fluorescent channels corresponding to CD86 and CD206 in each 
experiment as another overall determinant of macrophage polarization. 
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Immunohistochemistry  
Upon harvest, both tibialis anterior (TA) muscles were harvested from n=1 animal from 
each group. Each TA was flash frozen in chilled isopentane and cryosectioned. Six 7 μm 
sections were stained per muscle from regions spread at least 150 μm apart.  
Immunofluorescence slides were fixed in cold methanol for 10 minutes, rinsed with PBS 
for 5 minutes, blocked with 20% normal goat serum (NGS) in 2% bovine serum albumin 
(BSA), then incubated with primary antibodies against F4/80 (BioLegend BM8, Rat IgG2a 
anti-mouse F4/80) and Fizz1 (Peprotech 500-P215, Rabbit Polyclonal anti-Mouse 
RELMβ) at 1:500 20% NGS + 2% BSA at 4°C overnight. Primary antibody was removed 
from sections, then incubated with Goat Anti-Rat Alexa Fluor 488 and Goat Anti-Mouse 
Alexa Fluor 647 secondary antibodies (Thermo Fisher) at 1:500 in 20% NGS + 2% BSA for 
1 hour at room temperature. Slides were rinsed in PBS and mounted in Vectashield + 
DAPI (Vector). 20x immunofluorescence mosaics and 40x oil objective single extended 
focus images were taken with an Axio Imager.M2 microscope and rendered in 








Immunomodulatory effects of hydrogel in wild type and dystrophic mice. 
Potential immunomodulatory effects of the hydrogel were tested in comparison to 
saline in both wild-type C57BL/6 and dystrophic mdx-5Cv mice. Cryosections of injected 
TA muscles revealed the presence of F4/80+Fizz1+ macrophages in hydrogel-injected 
muscles, but not saline (Figure 3.1). Single-cell suspensions were obtained from each 
muscle and analyzed by FACS (Supplementary Figure 3.1). Macrophages 
(CD45+CD11b+F4/80+MHCII+) were prominent in all hydrogel-injected conditions (Figure 
3.2) with significantly more CD206+ macrophages found in hydrogel-injected wild type 
and dystrophic mice (Figure 3.2C).  CD86+CD206+ macrophages were most prominent in 
saline-injected dystrophic mice. Analysis of mean fluorescence intensity (MFI) 
(Supplementary Figure 3.3) indicated reductions in CD86-associated fluorophore signal 
in hydrogel-injected mice compared to saline, which was significant in dystrophic mice.   
No significant differences were observed in CD206-associated fluorophore MFI between 
groups, but corresponding decreases in CD86-fluorophore signal indicate an overall 
polarization away from CD86 and towards CD206 in hydrogel-injected mice. 
Inguinal lymph nodes, which are most proximal to injected muscles, showed significantly 
elevated expression of IL-4 in hydrogel-injected mice of both genotypes, but differences 
in IL-10 expression were only observed in wild-type mice (Figure 3.3). 
 
Effects of hydrogel and myostatin inhibitor on macrophage populations. 
In addition to the HA-ECM hydrogel, each of its individual components (HA-NHS, M-
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ECM) was injected into aged mdx-5Cv mice to evaluate their immunomodulatory 
properties. Since the hydrogel demonstrated the ability to deliver RK35 in vivo (Figure 
2.5), additional mice were injected with RK35 in saline and hydrogel. 
Immunofluorescence revealed F4/80+Fizz1+ macrophages in ECM, hydrogel, and 
hydrogel + RK35 mice (Figure 3.4). Cytometric analysis (Figure 3.5) revealed significantly 
reduced numbers of CD11b+ cells in M-ECM and RK35 injected mice. (Supplementary 
Figure 3.5), and significantly greater percentages of CD86+ (M1) and CD86+CD206+ 
macrophages in mice injected with HA-NHS. Hydrogel injected mice exhibited 
significantly more CD206+ macrophages; co-delivery of RK35 with the hydrogel also 
induced the CD86+CD206+ population. MFI analysis revealed a shift in macrophage 
polarization towards CD86 in HA-NHS treated mice (Supplementary Figure 3.3). 
 
Effects of hydrogel and myostatin inhibitor on T cell populations and cytokine signaling. 
Mice injected with hydrogel + RK35 exhibited elevated levels of CD3+ T cells compared 
to all other groups (Supplementary Figure 3.5). FACS revealed significantly greater 
numbers of CD4+ cells (Figure 3.6A) and Foxp3+ regulatory T cells (Figure 3.6B) in mice 
injected with both RK35 and hydrogel, more than any other group. Mice injected with 
hydrogel + RK35 also exhibited elevated levels of IL-17+ T cells (Supplementary Figure 
3.5). Inguinal lymph nodes showed elevated expression of IL-4 in ECM, hydrogel, and 
hydrogel+RK35 injected mice. No substantial differences were detected in IL-10, and a 
slight TNF-α increase was detected in hydrogel+RK35-injected mice (Figure 3.7).  No 
other significant differences were observed in IL-17, IL-6, IL-1β, IFN-ϒ, Arg1, or Retn1α. 
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Discussion 
This set of experiments represents the first evaluation of the effects of implanted 
biomaterials and myostatin inhibition on the skeletal muscle immune microenvironment 
in DMD. Immunofluorescence images of hydrogel-injected muscles revealed the 
presence of CD206+ macrophages (Figure 3.1, Figure 3.4), which was further confirmed 
with flow cytometry (Figure 3.2, 3.5). Additionally, mice injected with the hydrogel 
demonstrated significantly elevated interleukin-4 expression in local draining lymph 
nodes (Figure 3.3, 3.6). Finally, analysis of CD3+ T cell populations via flow cytometry 
revealed significantly elevated numbers of CD3+ T cells, CD3+CD4+ T helper cells, 
CD3+CD4+Foxp3+ regulatory T cells, and IL-17+ secreting T cells in mice injected with the 
myostatin inhibitor RK35 delivered via hydrogel (Figure 3.5, Supplementary Figure 3.5). 
 
The modulation of M2-like CD11b+F4/80+CD11c+/-CD206hiCD86+MHCII+ scaffold-
associated macrophages by implanted biomaterials has been established previously 
[83], and their role alongside CD4+ T cells in promoting regenerative outcomes in 
biomaterials-implanted mice is also well known [81]. Although there is significant 
potential for mechanisms of the immune system to go awry within the context of 
chronic injury or diseases such as DMD [58], macrophage polarization remained intact in 
dystrophic mice at one week post-injection (Figure 3.1). Foxp3+ regulatory T cells, an 
immune cell population responsible for mediating overall immune responses and 
facilitating the transition of macrophages from the M1 to the M2 phenotype in skeletal 
muscle [58], have been previously targeted for upregulation in dystrophic mdx mice via 
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treatment with IL-2/anti-IL-2 complexes that specifically act on these cells, leading to 
consequent increases in IL-10, reduced expression of cyclooxygenase-2, and reduction 
of pathologic muscle inflammation and injury [99]. Here, we observed a substantial 
upregulation of Foxp3+ regulatory T cells in mice injected with both hydrogel and the 
myostatin inhibitor RK35, a phenomenon not observed with RK35, the hydrogel, or any 
of the individual hydrogel components (Figure 3.5). This elevation of the regulatory T 
cell population was, however, insufficient to significantly increase expression of 
interleukin 10 in inguinal lymph nodes of dystrophic mdx mice (Figure 3.6), as observed 
in comparable wild-type animals (Figure 3.3). Nonetheless, this synergistic upregulation 
observed with both hydrogel and myostatin inhibitor delivered together suggests the 
existence of a novel immunomodulatory function for this combination. Future studies 
with co-delivery of hydrogel and RK35 separately administered systemically, 
intramuscularly, or in other controlled release vehicles such as polymeric fibers or 
spheres could be used to determine whether this effect is simply due to the presence of 
RK35 in conjunction with hydrogel, or its localization and/or sustained release.  
 
A great deal of work remains in determining the underlying mechanisms driving the pro-
regenerative effect of the hydrogel and myostatin inhibitor. Given the complex temporal 
kinetics of immune-mediated regulation of muscle [58], characterization of the scaffold 
immune environment at shorter or longer timepoints may add an additional layer of 
understanding to the host response to this material. In addition to the extracellular 
matrix present in the hydrogel, hyaluronic acid also has complex, variable effects on the 
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immune system through direct interaction with RHAMM and CD44 [100] that may affect 
local immune responses to the material. Myostatin inhibition has previously been 
shown to ameliorate TNF-α-mediated rheumatoid arthritis in mice [101], but its effects 
on muscle immunology are still relatively unknown. Specific isolation and transcriptome 
characterization of isolated specific immune cell populations present could clarify the 
signaling mechanisms modulated in response to the hydrogel or RK35.  
 
Additionally, some limitations are also present with the mouse model. Even though 
mdx-5Cv mice demonstrates profound defects compared to wild-type mice [97], 
hindlimb skeletal muscles are not as symptomatically severe as those of DMD patients, 
or even other muscles within the same animal, such as the diaphragm. Evaluation of 
these materials in dystrophic mice with or without myostatin inhibitor in more 
profoundly affected muscles such as the diaphragm, or in conjunction with injuries such 
as myotoxin, cryogenic, burn, or volumetric injury [102] may further elucidate the 
underlying mechanisms that shape the immune microenvironment in Duchenne 
Muscular Dystrophy. Comparative assessment of the hydrogel and myostatin inhibitor 
under healthy and injured conditions in both wild type and dystrophic mice could also 
potentially determine the effects of the immune environment and biomaterial on 
functional regeneration and repair, either through ex vivo physiologic assessment of 
individual muscles or whole-animal studies such as grip strength tests, hanging tests, 















Figure 3.1. Macrophage immunofluorescence in wild type and dystrophic mice. WT 
C57BL/6 (A) and mdx-5Cv (B) mice injected with saline (left images) or hydrogel (right 
images) were harvested at 7 days post-injection. Immunofluorescence images of 
cryosectioned TAs depict the presence of M2 macrophages (Fizz1, green) and general 































Figure 3.2. Macrophage polarization affected by hydrogel. Wild type C57BL/6 and mdx-
5Cv TAs injected with saline or hydrogel harvested at 7 days post-injection were analyzed 
via FACS. (A) General myeloid populations. (B) CD86+CD206-, CD86-CD206+, 
CD86+CD206+, and CD86-CD206- macrophages.  (C) CD86+CD206- and CD86-CD206+ 
macrophages. Legend applies to all figures. Populations shown as % CD45+ cells (left) 
and absolute number of CD45+ cells (right). Error bars are means +/- SEM, N=4 TA pairs 
per group. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 








































































































Figure 3.3. Cytokine expression in wild type and dystrophic mice.  WT C57BL/6 and 
mdx-5Cv mice injected with saline or hydrogel were harvested at 7 days post-injection. 
RNA was isolated from inguinal lymph nodes and used to determine local gene 
expression. IL-4 and IL-10 expression are presented as calibrated normalized relative 
quantities (CNRQ) over WT saline, normalized to B2M and TBP.  Legend applies to all 







































































    
 
   
 
   
 
 
Figure 3.4. Fizz1+ macrophages in hydrogel component- injected dystrophic mice. mdx-
5Cv mice injected with hydrogel components and/or RK35 were harvested at 7 days 
post-injection. Immunofluorescence images of cryosectioned TAs depict the presence of 
M2 macrophages (Fizz1, green) and general macrophage populations (F4/80, red). Scale 






































Figure 3.5. HA-ECM hydrogel and RK35 affect M2 macrophage polarization. Mdx-5Cv 
TAs injected with hydrogel components and/or RK35 harvested at 7 days post-injection 
were analyzed via FACS. (A) CD86+CD206-, CD86-CD206+, CD86+CD206+, and CD86-
CD206- macrophages.  (B) CD86+CD206- and CD86-CD206+ macrophages. Legend applies 
to all figures. Populations shown as % CD45+ cells (top/left) and absolute number of 
CD45+ cells (bottom/right). Legend applies to all figures. Error bars are means +/- SEM, 












































































































Figure 3.6. HA-ECM hydrogel and RK35 affect T cell polarization. Mdx-5Cv TAs injected 
with hydrogel components and/or RK35 harvested at 7 days post-injection were 
analyzed via FACS. (A) CD8+ and CD4+ T cells. (B) Foxp3+ regulatory T cells. Populations 
shown as % CD45+ cells (left) and absolute number of CD45+ cells (right). Legend applies 
to all figures. Error bars are means +/- SEM, N=4 TA pairs per group. * p<0.05, ** 



















































































Figure 3.7. Cytokine expression in hydrogel component-injected mice.  Mdx-5Cv mice 
injected with hydrogel components and/or RK35 were harvested at 7 days post-
injection. RNA was isolated from inguinal lymph nodes and used to determine local gene 
expression. Expression levels are presented as calibrated normalized relative quantities 
(CNRQ) over saline, normalized to B2M and TBP.  Legend applies to all figures. Legend 
applies to all figures. Error bars are means +/- SEM, N=4 inguinal lymph node pairs per 






























































































































































































Gene Forward Primer (5’  3’) Reverse Primer (5’  3’) 
B2M CACTGAATTCACCCCCACTGA TCTCGATCCCAGTAGACGGT 
TBP AGTGCCCAGCATCACTATTT GGTCCATGATTCTCCCTTTCTT 
IL-4rα GGTCACAGGAGAAGGGACGC AGCACCTTGGAAGCCCTACA 
IL-10 CAGGACTTTAAGGGTTACTTGGGT GCCTGGGGCATCACTTCTAC 
IL-17α TCAGCGTGTCCAAACACTGAG CGCCAAGGGAGTTAAAGACTT 
IL-6 CCAGGTAGCTATGGTACTCCAGAA GCTACCAAACTGGATATAATCAGGA 
IL-1β TGCCACCTTTTGACAGTGATG AAGCTGGATGCTCTCATCAGG 
TNFα ATGGCCTCCCTCTCATCAGT TGGTTTGCTACGACGTGGG 
IFNϒ TCAAGTGGCATAGATGTGGAA TGAGGTAGAAAGAGATAATCTGG 
Arg1 ACAAGACAGGGCTCCTTTCAG TAAAGCCACTGCCGTGTTCA 
Retn1α CAGCTGATGGTCCCAGTGAAT AGTGGAGGGATAGTTAGCTGG 
 
















Antigen Clone Fluorophore Dilution 
CD45 30-F11 Brilliant Violet 605 1:100 
CD11b M1/70 Alexa Fluor 700 1:400 
CD11c N418 Allophycocyanin 1:250 
F4/80 BM8 Phycoerythrin - Cy7 1:250 
CD86 GL-1 Brilliant Violet 510 1:200 
CD206 C068C2 Phycoerythrin 1:250 
MHCII (I-A/I-E) M5/114.15.2 Alexa Fluor 488 1:200 
Ly6c HK1.4 Peridinin Chlorophyll / Cy5.5 1:400 
Ly6g 1A8 Pacific Blue 1:400 
Viability -- eFluor780 1:2000 
 


























Antigen Clone Fluorophore Dilution 
CD3 145-2C11 Brilliant Violet 786 1:200 
CD4 RM4-5 Phycoerythrin – Texas Red 1:200 
CD8 SK1 Peridinin Chlorophyll / Cy5.5 1:200 
Foxp3 FJK-16s Fluorescein Isothiocyanate 1:100 
IL-17 TC11-18H10.1 Alexa Fluor 700 1:300 
CD45 30-F11 Horizon V500 1:300 
MHCII (I-A/I-E) M5/114.15.2 Brilliant Violet 711 1:2000 
F4/80 BM8 Phycoerythrin – Cy7 1:500 
CD86 GL-1 Allophycocyanin 1:400 
CD206 C068C2 Phycoerythrin 1:300 
CD11b M1/70 Pacific Blue 1:400 
Viability  Viability Aqua 1:2000 
 
















WT Saline 1 152500 MDX Saline 1 556000 
WT Saline 2 264000 MDX Saline 2 821000 
WT Saline 3 88000 MDX Saline 3 375000 
WT Saline 4 146600 MDX Saline 4 352000 
    WT Hydrogel 1 868000 MDX Hydrogel 1 251900 
WT Hydrogel 2 223200 MDX Hydrogel 2 645000 
WT Hydrogel 3 709000 MDX Hydrogel 3 446000 
WT Hydrogel 4 387000 MDX Hydrogel 4 826000 
 
Supplementary Table 3.1. Cell counts for samples in wild type vs. mdx study. Cell 
counts from each sample determined by “live” gating with Countess II-FL cell counter 














MDX Saline 1 199400 MDX Hydrogel 1 157200 
MDX Saline 2 264000 MDX Hydrogel 2 146600 
MDX Saline 3 58600 MDX Hydrogel 3 256000 
MDX Saline 4 105600 MDX Hydrogel 4 334000 
    MDX HA-NHS 1 292000 MDX RK35 1 98600 
MDX HA-NHS 2 274000 MDX RK35 2 210000 
MDX HA-NHS 3 167800 MDX RK35 3 69200 
MDX HA-NHS 4 290000 MDX RK35 4 288000 
    MDX M-ECM 1 137200 MDX Hydrogel + RK35 1 268000 
MDX M-ECM 2 199400 MDX Hydrogel + RK35 2 194800 
MDX M-ECM 3 260000 MDX Hydrogel + RK35 3 306000 
MDX M-ECM 4 268000 MDX Hydrogel + RK35 4 290000 
 
Supplementary Table 3.2. Cell counts for samples in mdx hydrogel study. Cell counts 
from each sample determined by “live” gating with Countess II-FL cell counter (Thermo 

















Supplementary Figure 3.1. FACS gating schematic for macrophage populations. Note: 
Ly6c / Ly6g not used for mdx hydrogel component study. 
 
 
Single cells Live CD45+ 





Supplementary Figure 3.2. Macrophage MFI in wild type vs. mdx hydrogel experiment. 
Left: CD86 (BV 510 signal). Right: CD206 (PE signal). Legend applies to all figures. Error 











































Supplementary Figure 3.3. Macrophage MFI in mdx hydrogel component experiment. 
Left: CD86 (APC signal). Right: CD206 (PE signal). Legend applies to all figures. Error bars 





















































Supplementary Figure 3.4. FACS gating schematic for T cell populations. 
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Supplementary Figure 3.5. Hydrogel and RK35 affect CD11b+, CD3+, and IL-17+ 
populations. Mdx-5Cv TAs injected with hydrogel components and/or RK35 harvested at 
7 days post-injection were analyzed via FACS. (A) CD11b+ cells. (B) CD3+ T cells. (B) IL-17+ 
T cells. Populations shown as % CD45+ cells (left) and absolute number of CD45+ cells 
(right). Legend applies to all figures. Error bars are means +/- SEM, N=4 TA pairs per 



















































































































Despite decades of development, cellular therapies for the treatment of DMD have 
remained largely ineffective. Here we describe the in vivo characterization of a novel 
population of human embryonic stem cell derived muscle progenitor cells for use in cell 
therapy, as well as the application of the injectable biomaterial hydrogel described in 
Chapter 2 to increase the effectiveness of their transplantation. Human stem-cell 
derived myoblasts injected into immunodeficient mice formed human muscle fibers in 
vivo and occupied the local progenitor cell niche, driving long term repair after injury. 
Transplantation of cells with the hydrogel promoted their viability at short-term 
timepoints, and a long-term pilot study revealed their capability to restore Dystrophin in 
immunodeficient dystrophic mice. Chapter 4 describes the first application of an 













The transplantation of healthy skeletal muscle progenitor cells into dystrophic recipients 
in order to partially or completely restore Dystrophin expression has been explored and 
evaluated by numerous groups since the late 1980s [40]. However, even after numerous 
preclinical and clinical trials, the results of cell therapy in DMD have been largely 
ineffective [47]. Obtaining sufficient numbers of transplant-competent muscle 
progenitor cells remains a difficult process, transplanted cell viability tends to be poor, 
and donor cell engraftment in terms of Dystrophin restoration and functional outcomes 
has largely been clinically insignificant.  
 
Here, human skeletal muscle progenitor cells derived with a previously described dual-
SMAD inhibition strategy [86] were evaluated for their capacity to serve as donor cells 
to not only form human muscle fibers but also act as the primary driver of skeletal 
muscle repair after injury. Additionally, the injectable hyaluronic acid – skeletal muscle 
ECM hydrogel characterized in Chapter 2 was utilized to promote the effectiveness of 
muscle myoblast transplantation in short-term and long-term studies. Through direct 
visualization and semi-quantitative assessment of cell survival and donor-derived 
myofiber formation, both the hydrogel and human pluripotent stem cell derived 





Materials and Methods 
Characterization of hESC derived myoblasts 
Human embryonic stem cell derived myoblasts were derived by the Lee Lab as described 
in Choi et. al. [86], via treatment of hESCs with CHIR99021 for 4 days, followed by DAPT 
treatment for 8 days, and further maintenance in culture for at least 18 days to allow for 
differentiation into the myogenic lineage [86]. 2-6 month old male NOD-Rag1null-IL2rgnull 
(NRG) or NOD-SCID-IL2rgnull (NSG) mice (Jackson Laboratories) mice were irradiated with 
18 Gy in the left or both hindlimbs with either a Shepherd Mark I (JL Shepherd) or a 
micro-CT guided Small Animal Radiation Research Platform (Xstrahl) [104] in order to 
ablate the endogenous satellite cell population. After three days, irradiated TAs were 
injured via injection of 100 μL 10 mM cardiotoxin (Naja Mossambica, Sigma) or 50 μL 
1.2% BaCl2 (Sigma) [102]. 24 hours after injury, 1-3 x 106
 
cells were injected into the left 
TA, with the right leg serving as an uninjected control.  
 
All TA muscles were harvested 4-8 weeks after each injection; serially injured mice 
received a second TA injury of 50 μL 1.2% BaCl2 at six weeks post-transplantation and 
were harvested two weeks later. TA muscles were flash frozen in chilled isopentane and 
7 μm cryosections were taken. Slides were fixed in cold methanol and blocked with 20% 
normal goat serum (NGS) in 2% bovine serum albumin (BSA). Fixed slides were 
incubated with primary antibodies against human lamin A+C (NCL-LAM-AC, mouse 
IgG2b, 1:100, Leica), pan-species Pax7 (PAX7, mouse IgG1, 1:1, DSHB), human laminin 
(2E8, mouse IgG2a, 1:100, DSHB), and human Dystrophin (MANDYS106, mouse IgG2a, 
66 
1:100, Leica), and secondary antibodies (goat anti-mouse IgG1 Alexa Fluor 488 1:500, 
goat anti-mouse IgG2a Alexa Fluor 647 1:500, goat anti-mouse IgG2b Alexa Fluor 555 
1:500, Thermo Fisher). Pax7-stained slides underwent tyramide signal amplification 
(Thermo Fisher). Stained sections were mounted using Vectashield with DAPI (Vector 
Laboratories), and imaged using confocal (Olympus) or fluorescence microscopy (Zeiss). 
Comparison of N=2-3 serially injured muscles versus uninjured controls was performed 
via Mann-Whitney test in Prism (Graphpad). 
 
Short-term transplantation of hydrogel-injected myoblasts 
For semiquantitative analysis, 1 month old male immunodeficient NOD-Rag1null-IL2rgnull 
(NRG) mice (Jackson Laboratories) were bilaterally injured via intramuscular injection of 
100 μL 10 μM cardiotoxin (Roche) [102] into shaved tibialis anterior (TA) muscles. 24 
hours post-injury, 0.5x106 LHCN-LUC7 immortalized human myoblasts [95] suspended in 
50 μL PBS or 6% w/v HA-NHS:M-ECM 1:3 hydrogel were subfascially injected above each 
TA muscle as described previously. 7 days after injection, muscles were frozen in chilled 
isopentane, cryosectioned, stained with primary antibodies against human lamin A+C 
(NCL-LAM-AC, mouse IgG2b, 1:100, Leica) and secondary antibodies (goat anti-mouse 
IgG2b Alexa Fluor 555 1:500, Thermo Fisher) and imaged using fluorescence microscopy 
(Zeiss). Human Lamin A+C+ nuclei present in each section were manually counted in 
ImageJ. N=6 sections were analyzed per muscle from regions at least 150 μm apart and 
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used to calculate percent cell survival.  4 muscles from n=2 animals were analyzed per 
group. All parameters were analyzed via two-way ANOVA in Prism (Graphpad). 
 
For cytometric analysis, 1.5 month old male immunodeficient dystrophic NOD-SCID-
IL2rγ—mdx-4Cv (NSG-4Cv) mice (University of Minnesota) [105] were irradiated with 18 
Gy X-ray radiation with a micro-CT guided Small Animal Radiation Research Platform 
(Xstrahl) [104], intramuscularly injured with 50 μL 1.2% BaCl2 after 24 hours [102], and 
transplanted with 1x106 human ES-derived GFP+ muscle progenitor cells (unpublished) in 
50 μL PBS or hydrogel subfascially above the injured TA muscle (n=5 per group) 24 hours 
after injury. After 10 days post-transplantation, mice were euthanized, TA muscles were 
removed, and a single cell suspension was yielded as described previously [106]. Each 
sample was analyzed using a FACS Calibur + CellQuest Pro (BD), and the relative 
percentages of transplanted GFP+ cells were determined for each sample. Sample group 
means were compared via Mann-Whitney test using Prism (Graphpad). 
 
Long-term transplantation of hydrogel-injected myoblasts 
1-2 month old male immunodeficient dystrophic NOD-SCID-IL2rγ—mdx-4Cv (NSG-4Cv) 
mice were irradiated with 18 Gy X-ray radiation with a micro-CT guided Small Animal 
Radiation Research Platform (Xstrahl) [104], intramuscularly injured with 50 μL 1.2% 
BaCl2 [102] after 24 hours, and transplanted with 1x106 hESC derived myoblasts [86] in 
50 μL PBS or 6% w/v HA-NHS:M-ECM 1:3 hydrogel alone or with 10.75 μg RK35 as 
described previously (n=1 each). After 4 months post-transplantation, mice were 
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euthanized and TA muscles were removed. Cryosections were obtained and stained 
with primary antibodies against human lamin A+C (Mouse IgG2b, 1:100, Leica), pan-
species Pax7 (IgG1, 1:1, DSHB), pan-species Dystrophin (Rabbit, 1:100, Abcam), human 
laminin (IgG2a, 1:100, DSHB), and human Dystrophin (IgG2a, 1:100, Leica), and 
secondary antibodies (goat anti-rabbit Alexa Fluor 488 1:500, goat anti-mouse IgG1 
Alexa Fluor 488 1:500, goat anti-mouse IgG2a Alexa Fluor 647 1:500, goat anti-mouse 
IgG2b Alexa Fluor 555 1:500, Thermo Fisher). Pax7-stained slides were also subjected to 
tyramide signal amplification (Thermo Fisher). Stained sections were mounted using 
Vectashield mounting medium with DAPI (Vector Laboratories), and imaged using 
fluorescence microscopy (Zeiss). Observed human Laminin+ and human Dystrophin+ 
fibers were counted from six 7 μm cryosections from each muscle taken at least 150 μm 










In vivo characterization of human pluripotent stem cell derived myoblasts. 
Human pluripotent stem cells derived to the myogenic lineage using a dual-SMAD 
inhibition strategy [86] were transplanted into irradiated, myotoxin injured tibialis 
anterior (TA) muscles of immunodeficient mice. At 4 weeks post-injection (Figure 4.1), 
viable human nuclei were observed in transplanted TAs as determined by positive 
staining for the nuclear marker human Lamin A+C. Human skeletal muscle laminin was 
also observed, consistent with mature myofibers. Some progenitor cells localized within 
human laminin+ fibers, occupying the satellite cell niche (Figure 4.1 inset).  
 
Niche occupancy of progenitors was further verified by immunofluorescence labeling of 
transplanted muscles with antibodies against Pax7, a marker of satellite cells. Co-
localization of Pax7 with human Lamin A+C, which is only present in donor-derived 
human nuclei, confirmed the occupancy of donor myoblasts in the satellite cell niche 
(Figure 4.1). Since local satellite cells are the primary mediators of skeletal muscle repair 
after injury, transplanted muscles were subjected to a secondary myotoxin injury to 
assess this functionality in donor-derived myoblasts. Analysis of injured transplanted 
TAs revealed a greater proportion of human Laminin+ and human Dystrophin+ fibers 





Effects of hydrogel on short-term transplantation of human muscle progenitor cells. 
The hydrogel described in Chapter 2 was further explored by determining its ability to 
deliver cells in vivo. 24 hours after cardiotoxin injury, immunodeficient mice were 
transplanted with immortalized human myoblasts suspended in saline or hydrogel.  
After 1 week, visual assessment of each muscle revealed twice as many human nuclei in 
hydrogel-transplanted mice compared to saline-transplanted mice (Figure 4.3). This was 
confirmed with a human pluripotent stem cell-derived myoblast line [86] modified to 
constitutively expresses GFP. 10 days after transplantation of these cells into irradiated, 
myotoxin-injured immunodeficient dystrophic mice, single-cell populations analyzed by 
flow cytometry revealed a significantly greater percentage of donor-derived GFP+ cells in 
hydrogel-transplanted muscles when compared to saline (Figure 4.4). 
 
Effects of hydrogel on long-term transplantation of human muscle progenitor cells. 
Four months after irradiation, myotoxin injury, and transplantation of human embryonic 
stem cell-derived myoblasts into immunodeficient mice, muscles were cryosectioned 
and the number of human Laminin+ and Dystrophin+ fibers was counted. Significantly 
greater numbers of human Laminin+ (Figure 4.5A) and Dystrophin+ (Figure 4.5B) fibers 
were observed in hydrogel-transplanted mice compared to saline-transplanted mice. 
Furthermore, nuclei that co-stained human Lamin A+C+ and Pax7+ within human 
Dystrophin+ fibers were observed in both conditions, verifying the long-term ability of 
saline- and hydrogel-transplanted human pluripotent stem cell derived myoblasts to 
occupy the satellite cell niche. 
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Discussion 
In this study, increased numbers of donor-derived myoblasts were observed in mice 
transplanted with hydrogel compared to saline (Figures 4.3-4.4). The hydrogel may have 
conferred a number of positive effects on viability and engraftment through 
mechanisms established in other studies, including protection from a harsh host 
environment [49] or reduction of anoikis, programmed cell death that occurs in 
anchorage-dependent cells that are detached from the extracellular matrix [107]. One 
key property of the hydrogel that may have also played a role is the dispersion of 
transplanted cells; without adequate spreading, progenitor cells either localize 
predominantly around the injection site or adopt a perifascicular pattern of engraftment 
[108], preventing widespread formation of donor-derived myofibers in situ.  
 
The slow but defined gelation pattern established with the hydrogel (Figure 2.2) allows 
the gel to travel, but retain its position once injected.  Cross-linking between HA-NHS 
and locally available primary amines may further increase retention of transplanted cells 
locally, as the adhesive properties of NHS-conjugated polymers has been previously 
established [93]. Although subfascial injection was established as an efficient method to 
ensure sufficient spreading of the hydrogel (Figure 2.4), intramuscular injection of the 
hydrogel may allow for further dispersion and delivery of transplanted cells. Also, since 
myostatin inhibition has been previously demonstrated to have positive effects on 
skeletal muscle stem cell transplantation [109], future potential studies could 
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synergistically utilize both hydrogel and the myostatin inhibitor RK35 to further promote 
the engraftment efficiency of transplanted cells. 
 
Dystrophin-restored fibers and Pax7+ / human Lamin A+C+ co-stained nuclei were 
observed histologically in long-term transplanted muscles (Figure 4.5), but they were 
relatively rare. Cross sections are only representative of a small portion of an entire 
muscle; some information may be lost due to sampling bias. Purely visual confirmation 
of human muscle fiber formation also may not completely differentiate between true de 
novo donor-derived human muscle fibers and hybrid fibers formed with host muscle, 
originating due to ineffective ablation of satellite cell populations via irradiation or 
incomplete myotoxin injury. Whole-muscle outcomes of engraftment such as flow 
cytometry for GFP-labeled progenitor cells or Western blotting to precisely quantify 
levels of restored Dystrophin [110] may present a more representative evaluation of 
engraftment efficiency. Additionally, harvesting transplanted muscles at shorter or 
longer-term timepoints may be required to fully appreciate the effects of the hydrogel 
on donor-driven repair and regeneration. In the longer term, functional outcomes such 
as electrophysiology or whole-animal studies could also be utilized [103]. Still, despite 
the phenotypic severity of the mdx-5Cv mouse model [105], additional injury may be 




Some limitations do exist with the transplanted human pluripotent stem cell-derived 
myoblasts utilized in this study. Although they form myofiber-like structures that 
express human laminin (Figures 4.1-4.2), the expression of sarcolemmal proteins such 
as human Dystrophin (Figures 4.2, 4.5) and human Collagen IV (data not shown) remain 
extremely limited by comparison. The cells in this study were injected after weeks of 
culture post-derivation without any intermediate purification steps; these cells are 
technically a heterogeneous population, the transplantation of which may decrease 
myogenic efficiency, and has had some unintended consequences in the form of 
possible transdifferentiation in situ leading to the formation of counterproductive non-
muscular hypertrophy in some cases (data not shown). Purification of these cell 
populations prior to injection, potentially utilizing GFP or other markers, could 














Figure 4.1. Transplantation of hESC-derived myoblasts in vivo. Left panels: 1x106 
human embryonic stem cell derived myoblasts formed human muscle fibers in vivo. 
Donor-derived nuclei (green) and human skeletal muscle Laminin (red) co-localize 
(merge) are present at four weeks post-injection with some human nuclei present in the 
sublaminar space (inset).  Figure scale bar = 50 microns, inset scale bar = 5 microns. 
Right panels: Transplanted hESC-derived myoblasts repopulate the satellite cell niche, as 
determined by co-localization of human Lamin A+C (magenta) and Pax7 (green) in 
merged image of cryosectioned TA muscle at 6 weeks post-injection. Scale bar = 50 
microns. Images taken from [86] as authorized by Creative Commons Attribution CC-BY-
NC-ND 4.0. 
 
Figure 1  
Cell Reports 2016 15, 2301-2312DOI: (10.1016/j.celrep.2016.05.016)  
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Figure 4.2. Transplanted hESC-derived myoblasts drive repair after serial injury. Mice 
transplanted with human embryonic stem cell derived myoblasts were either harvested 
at 8 weeks (left column) or injured a second time at 6 weeks prior to harvest at 8 weeks 
(middle column). Average numbers of human Laminin+ (red, top row) and human 
Dystrophin+ (green, bottom row) were counted across whole cryosection mosaics.  No 













































































Figure 4.3. Hydrogel promotes immortalized human myoblast viability after 7 days. 
0.5x106 immortalized human myoblasts were bilaterally injected into the subfascial 
space of NRG mouse TA muscles 24 hours post-cardiotoxin injury. Immunofluorescence 
images depict cross-sections of muscles transplanted with cells in PBS (left) or hydrogel 
(right) 7 days post-transplantation. Scale bars = 200 microns, N=4. All error bars 
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Figure 4.4. Hydrogel promotes GFP+ hESMyo viability after 10 days. 1x106 human 
embryonic stem cell-derived myoblasts modified to express GFP were unilaterally 
injected into NOD-SCID-Il2ϒ- (NSG) mouse TA muscles 72 hours after irradiation and 24 
hours after BaCl2 injury.  GFP+ cells were isolated from transplanted TAs and quantified 
via FACS. Representative FACS plots shown to illustrate isolated population. N=5 mice 















































Figure 4.5. Hydrogel promotes hESMyo engraftment after 4 months. 1x106 human 
embryonic stem cell derived myoblasts were injected into NSG-4Cv mice with saline or 
hydrogel. (A) Number of human Laminin+ fibers.  Muscle cross-section boundaries 
outlined in white.  (B) Number of Dystrophin+ fibers. (C) Presence of Pax7+ / human 
Lamin A+C+ double-positive nuclei co-localized near human Dystrophin+ fibers. 6 
sections were counted from N=1 mouse per group. Data points on graphs represent 
mean values +/- SEM. ** p<0.01. Scale Bar = 200 microns. 
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In this body of work, the principles of biomaterials and tissue engineering were applied 
to develop a regenerative medicine strategy for the treatment of DMD. We created an 
injectable biomaterial, known as a hydrogel, with the goal of utilizing it as a carrier to 
facilitate the delivery of growth factors and muscle progenitor cells in murine models of 
Duchenne Muscular Dystrophy. The hydrogel is composed of hyaluronic acid 
succinimidyl succinate (HA-NHS), a modified form of the glycosaminoglycan 
functionalized with N-hydroxysuccinimide groups to promote crosslinking to local 
primary amines and subsequent hydrogel formation. This was combined with 
decellularized porcine skeletal muscle extracellular matrix (M-ECM), a material noted for 
its utility in tissue engineering applications and its ability to modulate type 2 immune 
responses to promote pro-regenerative outcomes in skeletal muscle.  
 
HA-NHS and M-ECM combined to form a hydrogel at physiologic temperatures in vitro, 
as determined by time sweep rheology.  The hydrogel was determined to be 
cytocompatible in vitro when immortalized human myoblasts were cultured on the 
material over the course of four days.  The hydrogel demonstrated excellent injectability 
and spreading when injected into the subfascial space above mouse tibialis anterior and 
quadriceps muscles, and was shown to degrade in situ over the course of 21 days. 
Additionally, the hydrogel promoted the controlled release of incorporated myostatin 
inhibitors in vitro and increase their bioactivity in vivo, both over the course of five days. 
 
81 
Given the role of the immune system in shaping the course of skeletal muscle repair, the 
immunomodulatory properties of the hydrogel were evaluated. Immunofluorescence-
labeled cryosections from wild type and dystrophic muscles revealed the elevated 
presence of Fizz1+ macrophages in hydrogel-injected muscles when compared to saline. 
This was further confirmed by flow cytometry, which verified elevated levels of CD206+ 
macrophages in hydrogel-injected wild type and dystrophic mice. Furthermore, elevated 
levels of the pro-regenerative type 2 cytokine interleukin-4 were observed in the 
inguinal lymph nodes of hydrogel-injected wild type and dystrophic mice. However, 
increased expression of the inflammation-mediating cytokine interleukin-10 was only 
observed in the inguinal lymph nodes of wild type hydrogel-injected mice. 
 
The immunomodulatory properties of the hydrogel were further characterized by 
evaluating its individual components (HA-NHS, M-ECM) in dystrophic mice.  Additionally, 
the potential immunomodulatory effects of myostatin inhibition were evaluated by 
analyzing the immune microenvironment of dystrophic mice injected with RK35 alone or 
RK35 in hydrogel. Immunofluorescence analysis revealed the presence of Fizz1+ 
macrophages in M-ECM, hydrogel, and hydrogel+RK35 injected dystrophic mouse 
muscles. Cytometric analysis confirmed the elevated presence of CD206+ macrophages 
in hydrogel and hydrogel+RK35 injected mice, and inguinal lymph node cytokine analysis 
revealed significantly elevated levels of interleukin-4 in M-ECM, hydrogel, and 
hydrogel+RK35 injected mice. Analysis of CD3+ T cell population subsets revealed 
significant increases in the CD4+ T helper cells and Foxp3+ regulatory T cells in mice 
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injected with hydrogel+RK35. Increases in these key cell populations, which mediate 
effective skeletal muscle regeneration, were not observed with any of the individual 
hydrogel components, the hydrogel alone, or the myostatin inhibitor alone, suggesting a 
novel immunomodulatory functionality present with the combination of biomaterials 
implantation and myostatin inhibition in dystrophic mice. 
 
The multifunctionality of the hydrogel was further evaluated by utilizing it as an 
injectable carrier for transplanted skeletal muscle stem cells. Human embryonic stem 
cells derived to the myogenic lineage via treatment with CHIR99021 and DAPT were 
transplanted into immunodeficient mice and verified to form human muscle fibers in 
situ, reoccupy the endogenous skeletal muscle progenitor cell niche, and promote long-
term repair after injury. Short-term evaluation of the hydrogel as a cell carrier revealed 
increased numbers of immortalized human myoblasts transplanted with the hydrogel 
visible in serial cryosections after 7 days, and increased numbers of GFP+ human 
embryonic stem cell derived myoblasts present in single cell suspensions derived from 
hydrogel-injected muscles 10 days after transplantation. A longer-term study of hESC-
derived myoblasts transplanted into immunodeficient dystrophic mice revealed their 
capability to reoccupy the satellite cell niche after 4 months, and increased numbers of 





Given the interdisciplinary nature of this project, which lies at the interface of 
bioengineering and skeletal muscle biology, numerous potential future experimental 
directions remain.  Proteomic analysis of extracellular matrix components of the 
hydrogel [111] could be used to isolate the specific factors that promote regeneration in 
vivo. Delivery of RK35 with HA-NHS or M-ECM alone could be used to not only 
determine mechanisms of increased bioactivity, but potential synergistic 
immunomodulatory effects as well. Efficacy of myostatin inhibitor delivery could be 
further assessed by morphometric, physiologic, or functional assays of RK35-injected 
muscles, and longer-term studies could further clarify the effect of the hydrogel. Co-
administration of hydrogel and RK35 in other form factors such as systemic, 
intramuscular, or extended-release formulations may help verify the role of sustained 
myostatin inhibition on the immune microenvironment in DMD. 
 
Immunomodulatory evaluation of the materials and myostatin inhibitor was only 
performed at 1 week; shorter or longer timepoints where different populations such as 
neutrophils, eosinophils, or regulatory T cells predominate could clarify the effects of 
both injected components on the entire course of immune-mediated skeletal muscle 
regeneration. Any one of these populations could also be isolated and subjected to 
transcriptome analysis. Systemic effects of these materials on distal lymph nodes or 
distal muscles such as the diaphragm (the most profoundly affected muscle in 
dystrophic mice) could also be evaluated. These materials were also only tested in 
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healthy wild type and dystrophic animals; various models of muscle injury [102] could 
be applied in conjunction with these genotypes in order to reveal defects in 
regeneration that could be positively mediated with the myostatin inhibitor or hydrogel. 
 
Eventually, future therapeutic developments could include combinatorial delivery of 
muscle progenitor cells and myostatin inhibitors with the hydrogel, potentially 
increasing the efficacy of cell therapy for DMD. Transplantation of progenitor cells with 
reporters to isolate specific cell populations such as Pax7 could not only promote 
transplantation efficacy, but also facilitate visualization and verification of engraftment. 
Given the profound effects of the immune system on skeletal muscle and local muscle 
progenitor cells, a hydrogel such as the one described here could not only create a 
microenvironment in which transplanted cells could survive and thrive, but also shape 
the host immune microenvironment to promote donor cell engraftment and myofiber 
formation in situ. The use of mouse myoblasts in transplantation assays could allow for 
the use of immunocompetent mice, allowing for elucidation of the direct effects of 
immunomodulation on cell transplantation efficiency. Overall, this study represents the 
first observation of the combined effect of biomaterials and myostatin inhibition on the 
musculoskeletal immune microenvironment, providing novel insights into potential 





1. Jane Larkindale, e.a., Cost of Illness for Neuromuscular Diseases in the United 
States. Muscle and Nerve, 2014. 49(3): p. 431-438. 
2. Jerry R. Mendell, C.S., Nancy D. Leslie, Kevin M. Flanigan, Roula al-Dahhak, Julie 
Gastier-Foster, Kelley Kneile, Diane M. Dunn, Brett Duval, Alexander Aoyagi, 
Cindy Hamil, Maha Mahmoud, Kandice Roush, Lauren Bird, Chelsea Rankin, 
Heather Lilly, Natalie Street, Ram Chandrasekar, Robert B. Weiss, Evidence-based 
path to newborn screening for Duchenne muscular dystrophy. Annals of 
Neurology, 2012. 71(3): p. 304-313. 
3. Hoffman, E.P., R.H. Brown, and L.M. Kunkel, Dystrophin: The protein product of 
the duchenne muscular dystrophy locus. Cell, 1987. 51: p. 919-928. 
4. Sahenk, Z. and J.R. Mendell, The muscular dystrophies: distinct pathogenic 
mechanisms invite novel therapeutic approaches. Current Rheumatology 
Reports, 2011. 13: p. 199-207. 
5. Kevin M. Flanigan, A.v.N., Diane M. Dunn, Jonathan Alder, Jerry R> Mendell, 
Robert B. Weiss, Rapid Direct Sequence Analysis of the Dystrophin Gene. 
American Journal of Human Genetics, 2003. 72(4): p. 931-939. 
6. Andrew H. Ahn, L.M.K., The Structural and Functional Diversity of Dystrophin. 
Nature Genetics, 1993. 3(4): p. 283-291. 
7. Rebecca J. Fairclough, M.J.W., Kay E. Davies, Therapy for Duchenne muscular 
dystrophy: renewed optimism from genetic approaches. Nature Reviews 
Genetics, 2013. 14(6): p. 373-378. 
8. Surinder M. Singh, N.K., Javier Cabello-Villegas, and Krishna M. G. Mallela, 
Missense mutations in dystrophin that trigger muscular dystrophy decrease 
protein stability and lead to cross-β aggregates. Proceedings of the National 
Academy of Sciences, 2010. 107(34): p. 15069-15074. 
9. Luca Cartegni, S.L.C., Adrian R. Krainer, Listening to silence and understanding 
nonsense: exonic mutations that affect splicing. Nature Reviews Genetics, 2002. 
3(4): p. 285-298. 
10. Christophe Beroud, S.T.-G., Masafumi Matsuo, Dalil Hamroun,, N.M. Veronique 
Humbertclaude, Marie-Pierre Moizard, Marie-Antoinette Voelckel,, and P.B. 
Laurence Michel Calemard, Martine Blayau, Christophe Philippe, Mireille Cossee, 
Michel Pages, Francois Rivier, Olivier Danos, Luis Garcia, Mireille Claustres, 
Multiexon skipping leading to an artificial DMD protein lacking amino acids from 
86 
exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular 
dystrophy. Human Mutation, 2007. 28(2). 
11. J.R. Mendell, R.T.M., R.C. Griggs, M.H. Brooke, G.M. Fenichel, J.P. Miller, W. King, 
L. Signore, S. Pandya, J. Florence, J. Schierbecker, J. Robison, K. Kaiser, S. Mandel, 
C. Arfken, and B. Gilder, Randomized, Double-Blind Six-Month Trial of Prednisone 
in Duchenne's Muscular Dystrophy. The New England Journal of Medicine, 1989. 
320(4): p. 1592-1597. 
12. Robert D. Griggs, P.M., Cheryl R. Greenberg, Darcy L. Fehlings, Alan Pestronk, 
Jerry R. Mendell, RIchard T. Moxley, Wendy King, John Kissel, Valerie Cwik, 
Michel Vanasse, Julaine M. Florence, Shree Pandya, Jordan S. Dubow, James M. 
Meyer, Efficacy and safety of deflazacort vs prednisone and placebo for 
Duchenne muscular dystrophy. Neurology, 2016. 87(20): p. 2123-2131. 
13. Maaike van Putten, M.H., Vishna Devi Nadarajah, Sandra H. van Heiningen, Ella 
van Huizen, Maarten van Iterson, Peter Admiraal, Tobias Messemaker, Johan T. 
den Dunnen, Peter A. C. 't Hoen, Annemieke Aartsma-Rus, The Effects of Low 
Levels of Dystrophin on Mouse Muscle Function and Pathology. PLoS One, 2012. 
7(2): p. e31937. 
14. Richard S. Finkel, K.M.F., Brenda Wong, Carsten Bönnemann, Jacinda Sampson, 
H. Lee Sweeney, Allen Reha, Valerie J. Northcutt, Gary Elfring, Jay Barth, Stuart 
W. Peltz, Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients 
with Nonsense Mutation Duchenne Muscular Dystrophy. PLoS One, 2013. 8(12). 
15. Manuel Haas, V.V., Pavel Balabanov, Tomas Salmonson, Serge Bakchine, Greg 
Markey, Martina Weise, Gabriele Schlosser-Weber, Henning Brohmann, 
Concepcion Prieto Yerro, Macarena Rodriguez Mendizabal, Violeta Stoyanova-
Beninska, Hans L. Hillege, European Medicines Agency review of ataluren for the 
treatment of ambulant patients aged 5 years and older with Duchenne muscular 
dystrophy resulting from a nonsense mutation in the dystrophin gene. 
Neuromuscular Disorders, 2015. 25(1): p. 5-13. 
16. Stuart P. McElroy, T.N., Leah S. Torrie, Emma Warbrick, Ulrike Gartner, Gavin 
Wood, W. H. Irwin McLean, A lack of premature termination codon read-through 
efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biology, 
2013. 11(6). 
17. Jerry R Mendell, L.R.R.-K., Zarife Sahenk, Kandice Roush, Loren Bird, Linda P. 
Lowes, Lindsay Alfano, Ann Maria Gomez, Sarah Lewis, Janaiah Kota, Vinod 
Malik, Kim Shontz, Christopher Walker, Kevin Flanigan, Marco Corridore, John R. 
Kean, Hugh D. Allen, CHris Shilling, Kathleen R. Melia, Peter Sazani, Jay B. Saoud, 
Edward M. Kaye, the Eteplirsen Study Group, Eteplirsen for the treatment of 
Duchenne muscular dystrophy. Annals of Neurology, 2013. 74(5): p. 637-647. 
87 
18. M. Carrie Miceli, S.F.N., The case for eteplirsen: Paving the way for precision 
medicine. Molecular Genetics and Metabolism, 2016. 118(2): p. 70-71. 
19. Courtney S. Young, A.D.P., Exon Skipping Therapy. Cell, 2016. 167(5): p. 1144. 
20. Andrea M. Reinig, S.M., Daniel J. Berlau, Advances in the treatment of Duchenne 
muscular dystrophy: New and emerging pharmacotherapies. Pharmacotherapy, 
2017. 
21. Christopher R. Heier, J.M.D., Qing Yu, Blythe C. Dillingham, Tony Huynh, Jack H. 
Van der Meulen, Arpana Sali, Brittany K. Miller, Aditi Phadke, Luana Scheffer, 
James Quinn, Kathleen Tatem, Sarah Jordan, Sherry Dadgar, Olga C. Rodriguez, 
Chris Albanese, Michael Calhoun, Heather Gordish‐Dressman, Jyoti K. Jaiswal, 
Edward M. Connor, John M. McCall, Eric P. Hoffman, Erica K. M. Reeves, 
Kanneboyina Nagaraju, VBP15, a novel anti‐inflammatory and membrane‐
stabilizer, improves muscular dystrophy without side effects. EMBO Molecular 
Medicine, 2013. 5(10): p. 1569-1585. 
22. Kleopas A. Kleopa, A.D., Eleni Mavrikiou, Annita Ormisto, Theodoros Kyriakides, 
Naturally occurring utrophin correlates with disease severity in Duchenne 
muscular dystrophy. Human Molecular Genetics, 2006. 15(10): p. 1623-1628. 
23. Valeria Ricotti, S.S., Helen Roper, Imelda Hughes, Bina Tejura, Neil Robinson, 
Gary Layton, Kay Davies, Francesco Muntoni, Jonathon Tinsley, Safety, 
Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin 
Modulator, following Single- and Multiple-Dose Administration to Pediatric 
Patients with Duchenne Muscular Dystrophy. PLoS One, 2016. 11(4). 
24. Mary Lynn Mercado, A.R.A., Hiroki Hagiwara, Michael S. Rafii, Beatrice Lechner, 
Rick T. Owens, David J. McQuillan, Stanley C. Froehner, Justin R. Fallon, Biglycan 
targets dystrobrevin, syntrophin and nNOS to the muscle cell membrane. 
Federation of American Societies for Experimental Biology, 2006. 20(10): p. 
1724-1726. 
25. Alison R. Amenta, A.Y., Sasha Bogdanovich, Beth A. McKechnie, Mehrdad Abed, 
Tejvir S. Khurana, and Justin R. Fallon, Biglycan recruits utrophin to the 
sarcolemma and counters dystrophic pathology in mdx mice. Proceedings of the 
National Academy of Sciences, 2010. 108(2): p. 762-767. 
26. Jane T. Seto, J.N.R., Lindsey Muir, Jeffrey S. Chamberlain, Guy L. Odom, Gene 
replacement therapies for Duchenne muscular dystrophy using adeno-associated 
viral vectors. Current Gene Therapy, 2012. 12(3): p. 139-151. 
27. Scott Q. Harper, M.A.H., Christiana DelloRusso, Dongsheng Duan, Robert W. 
Crawford, Stephanie F. Phelps, Hollie A. Harper, Ann S. Robinson, John F. 
88 
Engelhardt, Susan V. Brooks, Jeffrey S. Chamberlain, Modular flexibility of 
dystrophin: Implications for gene therapy of Duchenne muscular dystrophy. 
Nature Medicine, 2002. 3: p. 253-261. 
28. Miki Sakamoto, K.Y., Madoka Yoshimura, Toshifumi Yokota, Takaaki Ikemoto, 
Misao Suzuki, George Dickson, Yuko Miyagoe-Suzuki, Shin'ichi Takeda, Micro-
dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx 
mice as a transgene. Biochemical and Biophysical Research Communications, 
2002. 293(4): p. 1265-1272. 
29. Duan, D., Dystrophin Gene Replacement and Gene Repair Therapy for Duchenne 
Muscular Dystrophy in 2016: An Interview. Human Gene Therapy Clinical 
Development, 2016. 27(1): p. 9-18. 
30. Jennifer A. Doudna, E.C., The new frontier of genome engineering with CRISPR-
Cas9. Science, 2014. 346(6213). 
31. Patrick D. Hsu, E.S.L., Feng Zhang, Development and Applications of CRISPR-Cas9 
for Genome Engineering. Cell, 2014. 157(6): p. 1262-1278. 
32. Christopher E. Nelson Chady H. Hakim, D.G.O., Pratiksha I. Thakore, Eirik A. 
Moreb, Ruth M. Castellanos Rivera, Sarina Madhavan, Xiufang Pan, F. Ann Ran, 
Winston X. Yan, Aravind Asokan, Feng Zhang, Dongsheng Duan, Charles A. 
Gersbach, In vivo genome editing improves muscle function in a mouse model of 
Duchenne muscular dystrophy. Science, 2016. 351(6271): p. 403-407. 
33. Chengzu Long, L.A., Alex A. Mireault, John R. McAnally, Hui Li, Efrain Sanchez-
Ortiz, Samadrita Bhattacharyya, John M. Shelton, Rhonda Bassel-Duby, Eric N. 
Olson, Postnatal genome editing partially restores dystrophin expression in a 
mouse model of muscular dystrophy. Science, 2016. 351(6271): p. 400-403. 
34. Mohammadsharif Tabebordbar, K.Z., Jason K. W. Cheng, Wei Leong Chew, 
Jeffrey J. Widrick, Winston X. Yan, Claire Maesner, Elizabeth Y. Wu, Ru Xiao, F. 
Ann Ran, Le Cong, Feng Zhang, Luk H. Vandenberghe, George M. Church, Amy J. 
Wagers, In vivo gene editing in dystrophic mouse muscle and muscle stem cells. 
Science, 2016. 351(6271): p. 407-411. 
35. Niclas E. Bengtsson, J.K.H., Guy L. Odom, Michael P. Phelps, Colin R. Andrus, R. 
David Hawkins, Stephen D. Hauschka, Joel R. Chamberlain, Jeffrey S. 
Chamberlain, Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates 
pathophysiology in a mouse model for Duchenne muscular dystrophy. Nature 
Communications, 2017. 8. 
89 
36. Boldrin, L., F. Muntoni, and J.E. Morgan, Are human and mouse satellite cells 
really the same? The journal of histochemistry and cytochemistry : official 
journal of the Histochemistry Society, 2010. 58: p. 941-55. 
37. Olguin, H.C. and B.B. Olwin, Pax-7 up-regulation inhibits myogenesis and cell 
cycle progression in satellite cells: a potential mechanism for self-renewal. Dev 
Biol, 2004. 275(2): p. 375-88. 
38. Brack, A.S., et al., Increased Wnt signaling during aging alters muscle stem cell 
fate and increases fibrosis. Science 2007. 317: p. 807-10. 
39. Scarda, a., et al., Increased adipogenic conversion of muscle satellite cells in 
obese Zucker rats. International journal of obesity (2005), 2010. 34: p. 1319-27. 
40. Terry A. Partridge, J.E.M., Gary R. Coulton, Eric P. Hoffman, Louis M. Kunkel, 
Conversion of mdx myofibres from dystrophin-negative to -positive by injection of 
normal myoblasts. Nature, 1989. 337(6203): p. 176-179. 
41. Maurilio Sampaolesi, S.B., Giuseppe D’Antona, Nicolas Granger, Rossana 
Tonlorenzi, Anna Innocenzi, Paolo Mognol, Jean-Lauren Thibaud, Beatriz G. 
Galvez, Ines Barthélémy, Laura Perani, Sara Mantero, Maria Guttinger, Orietta 
Pansarasa, Chiara Rinaldi, M. Gabriella Cusella De Angelis, Yvan Torrente, Claudio 
Bordignon, Roberto Bottinelli, Giulio Cossu, Mesoangioblast stem cells 
ameliorate muscle function in dystrophic dogs. Nature, 2006. 444(7119): p. 574-
579. 
42. Emanuela Gussoni, Y.S., Corinne D. Strickland, Elizabeth A. Buzney, Mohamed K. 
Khan, Alan F. Flint, Louis M. Kunkel, Richard C. Mulligan, Dystrophin expression in 
the mdx mouse restored by stem cell transplantation. Nature, 1999. 401(6751): 
p. 390-394. 
43. Antonio Filareto, S.P., Radbod Darabi, Luciene Borges, Michelina Iacovino, Tory 
Schaaf, Timothy Mayerhofer, Jeffrey S Chamberlain, James M. Ervasti, R. Scott 
McIvor, Michael Kyba, and Rita C.R. Perlingeiro, An ex vivo Gene Therapy 
Approach to Treat Muscular Dystrophy Using inducible Pluripotent Stem Cells. 
Nature Communications, 2013. 4. 
44. Courtney S. Young, M.R.H., Natalia V. Ermolova, Haruko Nakano, Majib Jan, 
Shahab Younesi, Saravanan Karumbayaram, Chino Kumagai-Cresse, Derek Wang, 
Jerome A. Zack, Donald B. Kohn, Atsushi Nakano, Stanley F. Nelson, M. Carrie 
Miceli, Melissa J. Spencer, April D. Pyle, A Single CRISPR-Cas9 Deletion Strategy 
that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-
Derived Muscle Cells. Cell Stem Cell, 2016. 18(4). 
90 
45. Emanuela Gussoni, G.K.P., Andrea M. Lanctot, Khema R. Sharma, Robert G. 
Miller, Lawrence Steinman, Helen M. Blau, Normal dystrophin transcripts 
detected in Duchenne muscular dystrophy patients after myoblast 
transplantation. Nature, 1992. 356(6368): p. 435-438. 
46. Giulio Cossu, S.C.P., Sara Napolitano, Maria Pia Cicalese, Francesco Saverio 
Tedesco, Francesca Nicastro, Maddalena Noviello, Urmas Roostalu, Maria Grazia 
Natali Sora, Marina Scarlato, Maurizio De Pellegrin, Claudia Godi, Serena Giuliani, 
Francesca Ciotti, Rossana Tonlorenzi, Isabella Lorenzetti, Cristina Rivellini, Sara 
Benedetti, Roberto Gatti, Sarah Marktel, Benedetta Mazzi, Andrea Tettamanti, 
Martina Ragazzi, Maria Adele Imro, Giuseppina Marano, Alessandro Ambrosi, 
Rossana Fiori, Maria Pia Sormani, Chiara Bonini, Massimo Venturini, Letterio S 
Politi, Yvan Torrente, Fabio Ciceri, Intra‐arterial transplantation of HLA‐
matched donor mesoangioblasts in Duchenne muscular dystrophy. EMBO 
Molecular Medicine, 2015. 7(12): p. 1513-1528. 
47. Daniel Skuk, J.P.T., Cell therapy in muscular dystrophies: many promises in mice 
and dogs, few facts in patients. Expert Opinion on Biological Therapy, 2015. 
15(9): p. 1307-1319. 
48. Wagner, K.R. and A. McPherron, Loss of myostatin attenuates severity of 
muscular dystrophy in mdx mice. Annals of Neurology, 2002. 52: p. 832-835. 
49. Moyer, A.L. and K.R. Wagner, Regeneration versus fibrosis in skeletal muscle. 
Current Opinion in Rheumatology, 2011. 23: p. 568-73. 
50. McPherron, A.C., A.M. Lawler, and S.J. Lee, Regulation of skeletal muscle mass in 
mice by a new TGF-beta superfamily member. Nature, 1997. 387: p. 83-90. 
51. Markus Shuelke, e.a., Myostatin Mutation Associated with Gross Muscle 
Hypertrophy in a Child. New England Journal of Medicine, 2004. 350(26): p. 
2682-2688. 
52. Wagner, K.R., et al., Muscle regeneration in the prolonged absence of myostatin. 
Proceedings of the National Academy of Sciences 2005. 102: p. 2519-24. 
53. Li, Z.B., H.D. Kollias, and K.R. Wagner, Myostatin directly regulates skeletal 
muscle fibrosis. The Journal of Biological Chemistry, 2008. 283: p. 19371-8. 
54. Bo Li, Z., J. Zhang, and K.R. Wagner, Inhibition of myostatin reverses muscle 
fibrosis through apoptosis. Journal of cell science, 2012. 125: p. 3957-65. 
55. Craig Campbell, H.J.M., Jean K. Mah, Mark Tarnopolsky, Kathryn Selby, Ty 
McClure, Dawn M. Wilson, Matthew L. Sherman, Diana Escolar, Kenneth M. 
Attie, Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne 
91 
muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. 
Muscle and Nerve, 2016. 
56. James R. Apgar, M.M., Rita Agostinelli, Susan Benard, Peter Bialek, Mark 
Johnson, Yijie Gao, Mark Krebs, Jane Owens, Kevin Parris, Michael St. Andre, Kris 
Svenson, Carl Morris, Lioudmila Tchistiakova, Beyond CDR-grafting: Structure-
guided humanization of framework and CDR regions of an anti-myostatin 
antibody. mAbs, 2016. 8(7): p. 1302-1318. 
57. Erika L.F. Holzbaur, D.S.H., Nicholas Weber, Karen Wallace, Yijin She, Seung 
Kwak, Liudmilla A. Tchstiakova, Erin Murphy, Joseph Hinson, Riyez Karim, Xiang 
Yang Tan, Pamela Kelley, Kevin C. McGill, Gareth Williams, Carl Hobbs, Patrick 
Doherty, Margaret M. Zaleska, Menelas N. Pangalos, Frank S. Walsh, Myostatin 
inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. 
Neurobiology of Disease, 2006. 23(3): p. 697-707. 
58. Tidball, J.G., Regulation of muscle growth and regeneration by the immune 
system. Nature Reviews Immunology, 2017. 17(3): p. 165-178. 
59. S. Armando Villalta, B.D., Chiara Rinaldi, Michelle Wehling-Henricks, James G. 
Tidball, IFN-γ promotes muscle damage in the mdx mouse model of Duchenne 
muscular dystrophy by suppressing M2 macrophage activation and inhibiting 
muscle cell proliferation. The Journal of Immunology, 2011. 187(10): p. 5419-
5428. 
60. Joanne Tonkin, L.T., Robert D Sampson, Enrique Gallego-Colon, Laura Barberi, 
Daniel Bilbao, Michael D Schneider, Antonio Musarò, and Nadia Rosenthal, 
Monocyte/Macrophage-derived IGF-1 Orchestrates Murine Skeletal Muscle 
Regeneration and Modulates Autocrine Polarization. Molecular Therapy, 2015. 
23(7): p. 1189-1200. 
61. Davie, P.L.a.J.K., γ-interferon modulates myogenesis through the major 
histocompatibility complex class II transactivator, CIITA. Molecular and Cellular 
Biology, 2011. 31(14): p. 2854-2866. 
62. Davie, P.L.a.J.K., Interferon-γ Resets Muscle Cell Fate by Stimulating the 
Sequential Recruitment of JARID2 and PRC2 to Promoters to Repress Myogenesis. 
Science Signaling, 2013. 6(305). 
63. Daniela Palacios, C.M., Silvia Consalvi, Giuseppina Caretti, Valentina Saccone, 
Valentina Proserpio, Victor E. Marquez, Sergio Valente, Antonello Mai, Sonia V. 
Forcales, Vittorio Sartorelli, Pier Lorenzo Puri, TNF/p38α/Polycomb Signaling to 
Pax7 Locus in Satellite Cells Links Inflammation to the Epigenetic Control of 
Muscle Regeneration. Cell Stem Cell, 2010. 7(4): p. 455-469. 
92 
64. Swarnali Acharyya, S.M.S., Alfred S. Cheng, Katherine J. Ladner, Wei He, William 
Kline, Huating Wang, Michael C. Ostrowski, Tim H. Huang, Denis C. Guttridge, 
TNF Inhibits Notch-1 in Skeletal Muscle Cells by Ezh2 and DNA Methylation 
Mediated Repression: Implications in Duchenne Muscular Dystrophy. PLoS One, 
2010. 5(8). 
65. Dalia Burzyn, W.K., Dmitriy Kolodin, Jennifer L. Shadrach, Massimiliano Cerletti, 
Young Jang, Esen Sefik, Tze Guan Tan, Amy J. Wagers, Christophe Benoist, Diane 
Mathis, A special population of regulatory T cells potentiates muscle repair. . Cell, 
2013. 155(6): p. 1282-1295. 
66. Valerie A. Fadox, D.L.B., Anatole Konowal, Peter W. Freed, Jay Y. Wescott. Peter 
M. Henson, Macrophages that have ingested apoptotic cells in vitro inhibit 
proinflammatory cytokine production through autocrine/paracrine mechanisms 
involving TGF-beta, PGE2, and PAF. Journal of Clinical Investigation, 1998. 101(4): 
p. 890-898. 
67. Valerie A. Fadok, D.L.B., Lindsay Guthrie, Peter M. Henson, Differential Effects of 
Apoptotic Versus Lysed Cells on Macrophage Production of Cytokines: Role of 
Proteases. The Journal of Immunology, 2001. 166(11): p. 6847-6854. 
68. Jose E. Heredia, L.M., Francis M. Chen, Alisa A. Mueller, Rahul C. Deo, Richard M. 
Locksley, Thomas A. Rando, Ajay Chawla Type 2 Innate Signals Stimulate 
Fibro/Adipogenic Progenitors to Facilitate Muscle Regeneration. Cell, 2013. 
153(2): p. 376-388. 
69. S. Armando Villalta, A.S.R., Jeffrey A. Bluestone, The immune system in Duchenne 
muscular dystrophy: Friend or foe. Rare Diseases, 2015. 3(1). 
70. Cezar, C.A. and D.J. Mooney, Biomaterial-based delivery for skeletal muscle 
repair. Adv Drug Deliv Rev, 2015. 84: p. 188-97. 
71. Nenad Bursac, M.J., Thomas A. Rando, Synergizing Engineering and Biology to 
Treat and Model Skeletal Muscle Injury and Disease. Annual Review of 
Biomedical Engineering, 2015. 17: p. 217-242. 
72. Hyun-Wook Kang, S.J.L., In Kap Ko, Carlos Kengla, James J Yoo, Anthony Atala, A 
3D bioprinting system to produce human-scale tissue constructs with structural 
integrity. Nature Biotechnology, 2016. 34(3): p. 312-319. 
73. Koffler, J. and K. Kaufman-Francis, Improved vascular organization enhances 
functional integration of engineered skeletal muscle grafts. Proceedings of the 
National Academy of Sciences, 2011. 108: p. 14789-14794. 
93 
74. Fuoco, C., et al., Injectable polyethylene glycol-fibrinogen hydrogel adjuvant 
improves survival and differentiation of transplanted mesoangioblasts in acute 
and chronic skeletal-muscle degeneration. Skeletal muscle, 2012. 2: p. 24. 
75. Fuoco, C., et al., In vivo generation of a mature and functional artificial skeletal 
muscle. EMBP Molecular Medicine, 2015. 7(4): p. 411-22. 
76. Wolf, M.T., et al., Naturally derived and synthetic scaffolds for skeletal muscle 
reconstruction. Adv Drug Deliv Rev, 2015. 84: p. 208-21. 
77. Roberto Gaetani, C.Y., Neha Srikumar, Rebecca Braden, Pieter A. Doevendans, 
Joost P.G. Sluijter, Karen L. Christman, Cardiac-Derived Extracellular Matrix 
Enhances Cardiogenic Properties of Human Cardiac Progenitor Cells. Journal of 
Cell Transplantation, 2016. 25(9): p. 1653-1663. 
78. Sicari, B.M., et al., An acellular biologic scaffold promotes skeletal muscle 
formation in mice and humans with volumetric muscle loss. Science Translational 
Medicine, 2014. 6(234): p. 234ra58. 
79. Kaitlyn Sadtler, A.S., Matthew T. Wolf, Xiaokun Wang, Drew M. Pardoll, Jennifer 
H. Elisseeff, Design, clinical translation and immunological response of 
biomaterials in regenerative medicine. Nature Reviews Materials, 2016. 1. 
80. Jenna L. Dziki, B.M.S., Matthew T. Wolf, Madeline C. Cramer, Stephen F. Badylak, 
Immunomodulation and Mobilization of Progenitor Cells by Extracellular Matrix 
Bioscaffolds for Volumetric Muscle Loss Treatment. Tissue Engineering Part A, 
2016. 22(19-20): p. 1129-1139. 
81. Kaitlyn Sadtler, K.E., Brian W. Allen, Matthew T. Wolf, Hongni Fan, Ada J. Tam, 
Chirag H. Patel, Brandon S. Luber, Hao Wang, Kathryn R. Wagner, Jonathan D. 
Powell, Franck Housseau, Drew M. Pardoll, Jennifer H. Elisseeff, Developing a 
pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells. 
Science, 2016. 352(6283): p. 366-370. 
82. Jordan J. Green, J.H.E., Mimicking biological functionality with polymers for 
biomedical applications. Nature, 2016. 540(7633): p. 386-394. 
83. Kaitlyn Sadtler, B.W.A., Kenneth M. Estrelas, Franck Hosseau, Drew M. Pardoll, 
Jennifer H. Elisseeff, The Scaffold Immune Microenvironment: Biomaterial-
Mediated Immune Polarization in Traumatic and Nontraumatic Applications. 
Tissue Engineering Part A, 2016. 
84. Calve, S., et al., Hyaluronic acid, HAS1, and HAS2 are significantly upregulated 
during muscle hypertrophy. American Journal of Physiology Cell Physiology, 
2012. 303: p. C577-88. 
94 
85. Chang, C.Y., et al., Hyaluronic acid-human blood hydrogels for stem cell 
transplantation. Biomaterials, 2012. 33: p. 8026-8033. 
86. In Young Choi, H.L., Kenneth Estrellas, Jyothi Mula, Tatiana V. Cohen, Yuanfan 
Zhang, Christopher J. Donnelly, Jean-Philippe Richard, Yong Jun Kim, Hyesoo Kim, 
Yasuhiro Kazuki, Mitsuo Oshimura, Hongmei Lisa Li, Akitsu Hotta, Jeffrey 
Rothstein, Nicholas Maragakis, Kathryn R. Wagner, Gabsang Lee, Concordant but 
Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific 
Myoblasts Derived using a Human iPSC-Based Model. Cell Reports, 2016. 15(10): 
p. 2301-2312. 
87. Nenad Bursac, M.J., Thomas A. Rando, Synergizing Engineering and Biology to 
Treat and Model Skeletal Muscle Injury and Disease. Annual Review of 
Biomedical Engineering, 2015. 17: p. 217-242. 
88. Cristina Borselli, H.S., Frank Benesch-Lee, Dmitry Shvartsman, Christine Cezar, 
Jeff W. Lichtman, Herman H. Vandenburgh, David J. Mooney, Functional muscle 
regeneration with combined delivery of angiogenesis and myogenesis factors. 
Proceedings of the National Academy of Sciences, 2010. 107(8): p. 3287-3292. 
89. Borselli, C., et al., The role of multifunctional delivery scaffold in the ability of 
cultured myoblasts to promote muscle regeneration. Biomaterials, 2011. 32: p. 
8905-14. 
90. Harsha Kabra, Y.H., Hang Liang Lim, Mrityunjoy Kar, Gaurav Arya, Shyni 
Varghese, Biomimetic Material-Assisted Delivery of Human Embryonic Stem Cell 
Derivatives for Enhanced In Vivo Survival and Engraftment. ACS Biomaterials 
Science & Engineering, 2015. 1(1): p. 7-12. 
91. Jennifer M. Singelyn, J.A.D., Sonya B. Seif-Naraghi, Robert B. Littlefield, Pamela J. 
Schup-Magoffin, Karen L. Christman, Naturally derived myocardial matrix as an 
injectable scaffold for cardiac tissue engineering. Biomaterials, 2009. 30(29): p. 
5409-5416. 
92. Jessica A. DeQuach, J.E.L., Cynthia Cam, Diane Hu, Michael A. Salvatore, Farah 
Sheikh, Karen L. Christman, Injectable skeletal muscle matrix hydrogel promotes 
neovascularization and muscle cell infiltration in a hindlimb ischemia model. 
European Cells and Materials, 2012. 23: p. 400-412. 
93. Iossif Strehin, Z.N., Karun Arora, Thao Nguyen, Jennifer Elisseeff, A Versatile pH 
Sensitive Chondroitin Sulfate-PEG Tissue Adhesive and Hydrogel. BIomaterials, 
2010. 31(10): p. 2788-2797. 
94. Jonathan M. Zuidema, C.J.R., Ryan J. Gilbert, Faith A. Morrison, A protocol for 
rheological characterization of hydrogels for tissue engineering strategies. 
95 
Journal of Biomedical Materials Research Part B: Applied Biomaterials, 2013. 
102(5): p. 1063-1073. 
95. Chun-Hong Zhu, V.M., Raquel N. Cooper, Kamel Mamhaoui, Anne Bigot, Jerry W. 
Shay, James P. Di Santo, Gillan S. Butler-Browne, Woodring E. Wright, Cellular 
senescence in human myoblasts is overcome by human telomerase reverse 
transcriptase and cyclin- dependent kinase 4: consequences in aging muscle and 
therapeutic strategies for muscular dystrophies. Aging Cell, 2007. 6: p. 515-523. 
96. R. Scott Thies, T.C., Monique V. Davies, Kathy N. Tomkinson, Adele A. Pearson, 
Quazi A. Shakey, Neil M. Wolfman, GDF-8 Peopeptide Binds to GDF-8 and 
Antagonizes Biological Activity by Inhibiting GDF-8 Receptor Binding Growth 
Factors, 2001. 18: p. 251-259. 
97. Nicholas Beastrom, H.L., Allison Macke, Benjamin D. Canan, Eric K. Johnson,  
Christopher M. Penton, Brian K. Kaspar, Louise R. Rodino-Klapac, Lan Zhou, Paul 
M.L. Janssen, mdx5cv Mice Manifest More Severe Muscle Dysfunction and 
Diaphragm Force Deficits than Do mdx Mice The American Journal of Pathology, 
2011. 179(5): p. 2464-2474. 
98. Jianyu Li, D.M., Designing hydrogels for controlled drug delivery. Nature Reviews 
Materials, 2016. 1. 
99. S. Armando Villalta, W.R., Leonel Martinez, Amanjot Kaur, TIm Sparwasser, 
James G. Tidball, Marta Margeta, Melissa J. Spencer, Jeffrey A. Bluestone, 
Regulatory T cells suppress muscle inflammation and injury in muscular 
dystrophy. Science Translational Medicine, 2014. 6(258). 
100. Suniti Misra, V.C.H., Roger R. Markwald, Shibnath Ghatak, Interactions between 
Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of 
Inflammation and Cancer. Frontiers in Immunology, 2015. 6. 
101. Berno Dankbar, M.F., Daniela Brunert, Silvia Hayer, Svetlana Frank, Corinna 
Wehmeyer, Denise Beckmann, Peter Paruzel, Jessica Bertrand, Kurt Redlich, 
Christina Koers-Wunrau, Athanasios Stratis, Adelheid Korb-Pap, Thomas Pap, 
Myostatin is a direct regulator of osteoclast differentiation and its inhibition 
reduces inflammatory joint destruction in mice. Nature Medicine, 2015. 21(9): p. 
1085-1090. 
102. David Hardy, A.B., Mathilde Latil, Gregory Jouvion, David Briand, Cedric 
Thepenier, Quentin Pascal, Aurelie Guguin, Barbara Gayaraud-Morel, Jean-Mark 
Cavaillon, Shahragim Tajbakhsh, Pierre Rocheteau, Fabrice Chretien, 
Comparative Study of Injury Models for Studying Muscle Regeneration in Mice. 
PLoS One, 2016. 11(1). 
96 
103. Annemieke Aartsma Rus, M.v.P., Assessing Functional Performance in the Mdx 
Mouse Model. Journal of Visualized Experiments, 2014. 85. 
104. Wong, J., et al., High-resolution, small animal radiation research platform with x-
ray tomographic guidance capabilities. Int J Radiat Oncol Biol Phys, 2008. 71(5): 
p. 1591-9. 
105. Robert W. Arpke, R.D., Tara L. Mader, Yu Zhang, Akira Toyama, Cara-lin Lonetree, 
Nardina Nash, Dawn A. Lowe, Rita C.R. Perlingeiro, Michael Kyba, A New 
Immuno-, Dystrophin-Deficient Model, the NSG-mdx-4Cv Mouse, Provides 
Evidence for Functional Improvement Following Allogeneic Satellite Cell 
Transplantation. Stem Cells 2013. 31(8): p. 1611-1620. 
106. Partridge, T.A., Tissue Culture of Skeletal Muscle, in Basic Cell Culture Protocols, 
J.M.W. Jeffrey W. Pollard, Editor. 1997, Humana Press. p. 131-144. 
107. Lindsay A. Muir, C.E.M., Jeffrey S. Chamberlain, Prosurvival Factors Improve 
Functional Engraftment of Myogenically Converted Dermal Cells into Dystrophic 
Skeletal Muscle. Stem Cells and Development, 2016. 25(20): p. 1559-1569. 
108. Jinhong Meng, C.F.A., Shi-Wen Xu, Francesco Muntoni, Jennifer E. Morgan, 
Contribution of human muscle-derived cells to skeletal muscle regeneration in 
dystrophic host mice. PloS one, 2011. 6(3). 
109. Fakhfakh, R., S.-J. Lee, and J.P. Tremblay, Administration of a soluble activin type 
IIB receptor promotes the transplantation of human myoblasts in dystrophic 
mice. Cell transplantation, 2012. 21: p. 1419-30. 
110. Karen Anthony, V.A.-G., Laura E. Taylor, Adeline Vulin, Yuuki Kaminoh, Silvia 
Torelli, Lucy Feng, Narinder Janghra, Gisèle Bonne, Maud Beuvin, Rita Barresi, 
Matt Henderson, Steven Laval, Afrodite Lourbakos, Giles Campion, Volker 
Straub, Thomas Voit, Caroline A. Sewry, Jennifer E. Morgan, Kevin M. Flanigan, 
and Francesco Muntoni, Dystrophin quantification: Biological and translational 
research implications. Neurology, 2014. 83(22): p. 2062-2069. 
111. Vince Z. Beachley, M.T.W., Kaitlyn Sadtler, Srikanth S. Manda, Heather Jacobs, 
Michael R. Blatchley, Joel S. Bader, Akhilesh Pandey, Drew Pardoll, Jennifer H. 
Elisseeff, Tissue matrix arrays for high-throughput screening and systems 











2011-17: JOHNS HOPKINS UNIVERSITY. BALTIMORE, MD. PhD Candidate, Graduate 
Training Program in Cellular and Molecular Medicine.  
Dissertation: Development of a Regenerative Medicine Strategy for the Treatment of 
Duchenne Muscular Dystrophy. 
 
2011: BROWN UNIVERSITY. PROVIDENCE, RI. Master of Science in Biology.  
Dissertation: Synthesis and Evaluation of Time-Dependent Mucoadhesion of Novel 
Bioadhesive Polymers. 
 
2010: BROWN UNIVERSITY. PROVIDENCE, RI. Bachelor of Science in Biology with Honors.  
Thesis: Fabrication of Double-Walled Nanospheres by Sequential Phase Inversion 
Nanoencapsulation. 
 





2012-2017: PhD Candidate. Johns Hopkins University. Baltimore, MD.  
Co-Mentors: Dr. Kathryn Wagner, MD PhD (Director, Center for Genetic Muscle 
Disorders, Kennedy Krieger Institute) and Dr. Jennifer Elisseeff, PhD (Director, 
Translational Tissue Engineering Center, Johns Hopkins School of Medicine).  
Development of biomaterial hydrogel for use in myogenic progenitor cell 
transplantation and growth factor delivery for the treatment of muscular dystrophies. 
Analysis of regenerative capacity of transplanted human muscle stem cells. 
Determination of immunomodulatory properties of implanted biomaterials. 
 
2011: Rotation Student. Johns Hopkins University. Baltimore, MD.  
Mentor: Dr. Charles Rudin, MD PhD (Co-Director, Druckenmiller Center for Lung Cancer 
Research, Memorial Sloan Kettering Cancer Center).  
Investigation of the role of autophagy and apoptosis in small cell lung cancer. 
 
2009–2011: Research Assistant. Brown University. Providence, RI.  
98 
Mentor: Dr. Edith Mathiowitz PhD (Director, Biotechnology Graduate Program, Brown 
University). Fabrication and characterization of double-walled polymer nanospheres for 
use in drug delivery. In vivo rodent studies of uptake, biodistribution, and bioadhesion. 
2008–2009: Research Assistant. Brown University. Providence, RI.  
Mentor: Dr. Sorin Istrail PhD (Professor, Computer Science, Brown University).  
Study of cis -regulation of transcription factor expression and conversion of genetic 





K.N. Sadtler, B.W. Allen, K.M. Estrellas, J.D. Powell, F. Hosseau, D.M. Pardoll, J.H. 
Elisseeff. The Scaffold Immune Microenvironment: Biomaterial-Mediated Immune 
Polarization in Traumatic and Non-Traumatic Applications. Tissue Engineering Part A. 
October 2016. 
 
I.Y. Choi, H.T. Lim, K.M. Estrellas, J. Mula, T.V. Cohen, Y Zhang, C.J. Donnelly, J.P Richard, 
Y.J. Kim, H. Kim, Y. Kazuki, M. Oshimura, H. Li, A. Hotta, J. Rothstein, N. Margakis, K.R. 
Wagner, G. Lee. Concordant but varied phenotypes among patient-specific myoblasts of 
Duchenne muscular dystrophy revealed by human iPSC-based model. Cell Reports. May 
2016. 
 
K.N. Sadtler, K.M. Estrellas, B.W. Allen, M.T. Wolf, H. Fan, A.J. Tam, C. Patel, B.S. Luber, 
H. Wang, K.R. Wagner, J.D. Powell, F. Hosseau, D.M. Pardoll, J.H. Elisseeff. Developing a 
Pro-Regenerative Biomaterial Scaffold Micronevironment Requires T Helper 2 Cells. 
Science. April 2016. 
 
B. Laulicht, A. Mancini, N. Geman, D.Y. Cho, K.M. Estrellas, S. Furtado, R. Hopson, A. 
Tripathi, E. Mathiowitz. Bioinspired Bioadhesive Polymers: Dopa-Modified Poly(acrylic 
acid) Derivatives. Macromolecular Bioscience. September 2012. 
 
R.S. Patel, D.Y. Cho, C. Tian, A. Chang, K.M. Estrellas, D. Lavin, S. Furtado, E. Mathiowitz. 
Doxycycline delivery from PLGA microspheres prepared by a modified solvent removal 





K.M. Estrellas, J. Mula, K.N. Sadtler, L. Cheu, S. Madjumadar, L. Chung, M. Wolf, E. 
Velarde, I.Y. Choi, G. Lee, J.H. Elisseeff, K.R. Wagner. Injectable Biomaterial Increases the 
Myogenic Capacity of Transplanted Human Skeletal Muscle Stem Cells In Vivo. Tissue 
Engineering and Regenerative Medicine International Society Americas - Annual 
Meeting. San Diego, CA. December 2016. 
 
99 
K.M. Estrellas, K. Sadtler, S. Madjumadar, J. Mula, E. Velarde, L. Cheu, I.Y. Choi, H.T. Lim, 
G. Lee, J.H. Elisseeff, K.R. Wagner. Injectable Biomaterials Facilitates Controlled Release 
of Myostatin Inhibitors and Promotes Viability of Transplanted Myogenic Progenitor 
Cells In Vivo. 9th Annual Maryland Stem Cell Research Symposium. Silver Spring, MD. 
May 2016. 
 
K.M. Estrellas, T. Criswell, J. Temenhoff. Co-Chairs, Musculoskeletal Tissue Regeneration 
Concurrent Session. Tissue Engineering and Regenerative Medicine International Society 
Annual Conference and Exposition. Washington, DC. December 2014. 
 
K.M. Estrellas, J.H. Elisseeff, K.R. Wagner. Development of a Biomaterial-Based Hydrogel 
for the Delivery of Myogenic Progenitor Cells Towards the Treatment of Muscular 
Dystrophy. 7th Annual Maryland Stem Cell Research Symposium. Silver Spring, MD. 
December 2014. 
 
D.Y. Cho, C. Tian, K.M. Estrellas, Y.T. Liu, J.J. Reineke, S. Furtado, E. Mathiowitz. 
Bioadhesive Double-Walled Nanospheres as an Oral Insulin Delivery Platform. 38th 
Annual Meeting and Exposition of the Controlled Release Society. Baltimore, MD. July 
2011. 
 
L. Quattrochi, D.Y. Cho, K.M. Estrellas, N.L. Wicks, E. Oancea, E. Mathiowitz. 
Development of an Artificial Melanosome Utilizing a Lipid-Polymer Hybrid Microparticle. 
38th Annual Meeting and Exposition of the Controlled Release Society. Baltimore, MD. 
July 2011. 
 
D.Y. Cho, K.M. Estrellas, C. Tian, J. Reineke, E. Mathiowitz. A Novel Method for the 
Fabrication of Double-Walled Nanospheres by Sequential Phase Inversion 
Nanoencapsulation. 37th Annual Meeting and Exposition of the Controlled Release 
Society. Portland, OR. July 2010. 
 
D.Y. Cho, C. Tian, K.M. Estrellas, E. Mathiowitz. Effect of Encapsulation Method on 
Protein Loaded Nanospheres Fabricated by Phase Inversion Nanoencapsulation. 37th 






Rodents: Small Rodent Surgical Models (Cell Transplantation, Hydrogel/Biomaterials 
Implantation), Small Rodent Injury Models (Volumetric Muscle Defect, Muscle 
Myotoxins (Cardiotoxin, Notexin, Barium Chloride), Muscle Irradiation), Small Rodent 
Anesthesia (Isoflurane, Ketamine/Xylazine), Small Rodent Drug Administration 
(Intraperitoneal, Subcutaneous, Intramuscular), Small Rodent Functional Testing 
100 
(Treadmill Exhaustion, Grip Strength), Small Rodent Breeding/Husbandry and 
Genotyping. 
 
Cellular: Cell Isolation (Muscle Progenitors, Lymphoid/Myeloid Immune Cells), 
Multiplex/Multicolor Flow Cytometry Staining, Cell/Tissue Culture, Cell Viability 
(Live/DEAD), Cell Proliferation (MTS/MTT, AlmarBlue/PrestoBlue). 
 
Genetic: RNA Isolation, RNA Quantification (Nanodrop), cDNA Synthesis, Quantitiative 
RT-PCR (qPCR), DNA Isolation, PCR. 
 
Protein: Protein Isolation, Protein Quantification (BCA), Western Blotting, ELISA. 
 
Histology: Cryosectioning, Multiplex Immunofluorescence, Hematoxylin & Eosin (H&E), 
Masson’s Trichrome. 
 
Imaging: Mutiplex/Multicolor Epifluorescence Microscopy (Zeiss Axio Imager M2), 
Mutiplex/Multicolor Confocal Microscopy (Olympus FV1000), Brightfield Microscopy 
(Zeiss Axio Imager M2). 
 
Muscle: Cross-Sectional Area Muscle Regeneration Analysis, Muscle Histology and 
Immunofluorescence. 
 
Bioengineering: Cell Encapsulation, Animal Tissue Decellularization, Hydrogel 
Fabrication, Polymer Synthesis, Hydroxamate Assay, Rheology, Differential Scanning 
Calorimetry. 
 
Software: Zeiss AxioVision, Olympus FluoView, Microsoft Image Composite Editor (ICE), 





2016 Maryland State Champion, 3 Minute Thesis Competition - University of 
Maryland. Baltimore, MD. Summary of PhD thesis in three minutes. Explanation of 
complex scientific concepts to general audience. 
 
2016 3rd Place Winner, 3 Minute Thesis Competition - Johns Hopkins University. 
Baltimore, MD. Summary of PhD thesis in three minutes. Explanation of complex 
scientific concepts to general audience. 
 
2016 1st Place Winner, Baltimore Underground Science Space x Project Bridge Science 
Slam. Baltimore, MD. Summary of PhD thesis in three minutes. Explanation of complex 
scientific concepts to general audience. 
 
101 
2010 Graduate Honors, ScB Biology. Brown University. Providence, RI. Honors 
conferred upon Brown University ScB Biology graduates upon completion of thesis. 
 
2010 The Alfred H. Joslin Award for Student Leadership and Involvement. Brown 
University. Providence, RI. Awarded to graduating seniors who have demonstrated 






2015–17 Graduate Student Mentor, JHU Undergraduate Neuroscience Program. 
Baltimore, MD. Individualized mentorship / research training of JHU undergraduate 
student, Lindsay Cheu. 
 
2015–16 Co-Chair, Brown University Alumni Interviewing Program, Area 210. 
Baltimore, MD. Organized admissions interviews for ~300 Baltimore area high school 
applicants to Brown University. 
 
2014–17 Director of Operations, Baltimore Dance Crews Project Collective. 
Baltimore, MD. Scheduled rehearsals & logistical support for urban dance organization. 
 
2011–14 Workshop Coordinator/Instructor, Baltimore Dance Crews Project. 
Baltimore, MD. Planned beginner-advanced urban dance workshops for public 
audiences. 
 
2009-11  Primary Organizer, Free Open Hip Hop Dance Workshops. Brown 
University. Providence, RI. Planned intermediate-advanced urban dance workshops for 
public audiences. 
 
2009-11  Co-Director, imPulse Dance Company. Brown University. Providence, RI. 
Creative and logistical direction of a collegiate urban dance organization. 
 
2008–09 Co-Founder / Organizer, “Dancing With The Professors.” Brown 
University. Providence, RI. Co-developed charity event pairing Brown professors with 
Brown Ballroom Dance Team members. 
 
2007–08 Co-President, Filipino Alliance. Brown University. Providence, RI. Creative 









2016   Equity Research Extern. T. Rowe Price / BCI Equity Research Externship. 
Baltimore, MD. Performed due diligence on mid-cap life sciences companies and 
formulated biotech stock pitch. 
 
2013   Consulting Case Competition. Johns Hopkins University Graduate 
Consulting Club. Baltimore, MD. Participated in team-based business consulting life 
sciences case competition. 
 
2010–11  NSF EPSCoR Entrepreneurial Fellow. Slater Technology Fund. Providence, 
RI. Biopharmaceutical venture capital development and startup formation. 
 
2008–11 Intern. New Age Marketing, Inc. Conway, NH. Viability assessment of 
college marketing methods; production of training materials. 
 
